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Abstract
Pilot of a randomised controlled trial of the selective
serotonin reuptake inhibitor sertraline versus cognitive
behavioural therapy for anxiety symptoms in people with
generalised anxiety disorder who have failed to respond to
low-intensity psychological treatments as defined by the
National Institute for Health and Care Excellence guidelines
Marta Buszewicz,1* John Cape,2 Marc Serfaty,3,4 Roz Shafran,5
Thomas Kabir,6 Peter Tyrer,7 Caroline S Clarke1 and Irwin Nazareth1
1Research Department of Primary Care and Population Health, University College London,
London, UK
2Department of Clinical Health Psychology, University College London, London, UK
3Division of Psychiatry, University College London, London, UK
4The Priory Hospital North London, The Bourne, London, UK
5UCL Great Ormond Street Institute of Child Health, University College London, London, UK
6McPin Foundation, London, UK
7Centre for Mental Health, Imperial College London, London, UK
*Corresponding author m.buszewicz@ucl.ac.uk
Background: Generalised anxiety disorder (GAD) is common, causing unpleasant symptoms and impaired
functioning. The National Institute for Health and Care Excellence (NICE) guidelines have established
good evidence for low-intensity psychological interventions, but a significant number of patients will not
respond and require more intensive step 3 interventions, recommended as either high-intensity cognitive
behavioural therapy (CBT) or a pharmacological treatment such as sertraline. However, there are no
head-to-head comparisons evaluating which is more clinically effective and cost-effective, and current
guidelines suggest that treatment choice at step 3 is based mainly on patient preference.
Objectives: To assess clinical effectiveness and cost-effectiveness at 12 months of treatment with the
selective serotonin reuptake inhibitor (SSRI) sertraline compared with CBT for patients with persistent GAD
not improved with NICE-defined low-intensity psychological interventions.
Design: Participant randomised trial comparing treatment with sertraline with high-intensity CBT for
patients with GAD who had not responded to low-intensity psychological interventions.
Setting: Community-based recruitment from local Improving Access to Psychological Therapies (IAPT)
services. Four pilot services located in urban, suburban and semirural settings.
Participants: People considered likely to have GAD and not responding to low-intensity psychological
interventions identified at review by IAPT psychological well-being practitioners (PWPs). Those scoring ≥ 10
on the Generalised Anxiety Disorder-7 (GAD-7) anxiety measure were asked to consider involvement in
the trial.
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Inclusion criteria: Aged ≥ 18 years, a score of ≥ 10 on the GAD-7, a primary diagnosis of GAD diagnosed
on the Mini International Neuropsychiatric Interview questionnaire and failure to respond to NICE-defined
low-intensity interventions.
Exclusion criteria: Inability to participate because of insufficient English or cognitive impairment, current
major depression, comorbid anxiety disorder(s) causing greater distress than GAD, significant dependence
on alcohol or illicit drugs, comorbid psychotic disorder, received antidepressants in past 8 weeks or
high-intensity psychological therapy in previous 6 months and any contraindications to treatment with
sertraline.
Randomisation: Consenting eligible participants randomised via an independent, web-based,
computerised system.
Interventions: (1) The SSRI sertraline prescribed in therapeutic doses by the patient’s general practitioner
for 12 months and (2) 14 (± 2) CBT sessions delivered by high-intensity IAPT psychological therapists in
accordance with a standardised manual designed for GAD.
Main outcome measures: The primary outcome was the Hospital Anxiety and Depression Scale –
Anxiety component at 12 months. Secondary outcomes included measures of depression, social
functioning, comorbid anxiety disorders, patient satisfaction and economic evaluation, collected by
postal self-completion questionnaires.
Results: Only seven internal pilot participants were recruited against a target of 40 participants at
7 months. Far fewer potential participants were identified than anticipated from IAPT services, probably
because PWPs rarely considered GAD the main treatment priority. Of those identified, three-quarters
declined participation; the majority (30/45) were reluctant to consider the possibility of randomisation
to medication.
Limitations: Poor recruitment was the main limiting factor, and the trial closed prematurely.
Conclusions: It is unclear how much of the recruitment difficulty was a result of conducting the trial
within a psychological therapy service and how much was possibly a result of difficulty identifying
participants with primary GAD.
Future work: It may be easier to answer this important question by recruiting people from primary care
rather than from those already engaged in a psychological treatment service.
Trial registration: Current Controlled Trials ISCRTN14845583.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 45.
See the NIHR Journals Library website for further project information.
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Plain English summary
Generalised anxiety disorder (GAD) is common, distressing and can stop people leading a full life.It is often chronic and may be accompanied by depression. Current National Institute for Health and
Care Excellence guidelines outline the best initial treatments, but it is not clear whether medication or
psychological therapy works best for those not responding to simpler, low-intensity treatments. Both have
been found to be beneficial in randomised trials but have never been directly compared, so it is unclear
what to advise patients if simpler treatments have not worked. Currently the choice is left to the patient
and their doctors.
We planned a randomised trial of the medication sertraline versus intensive cognitive behavioural therapy
(CBT) for people with GAD that had not been responding to low-intensity psychological treatments. People
scoring highly on a specific anxiety measure (Generalised Anxiety Disorder-7), despite having received a
low-intensity intervention, were asked by the psychological practitioners treating them if they would
consider being assessed for the trial and randomised (allocated by chance) to either medication or
high-intensity CBT. We aimed to recruit via the Improving Access to Psychological Therapies services,
starting with four sites in London, the south-west and central England.
Fewer potential participants were identified than expected. Most who were identified declined involvement,
mainly because they did not want to risk being allocated to take medication, although some did not want
any research involvement. Only seven participants were recruited in 7 months. It may be easier to answer
this important question by recruiting people from primary care rather than from those already engaged in a
psychological treatment service.
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Scientific summary
Background
Generalised anxiety disorder (GAD) is characterised by excessive, uncontrollable and often irrational worry
that interferes with daily functioning and can cause physical symptoms. It is common, but, as symptoms
have to be present for at least 6 months for the diagnosis, it is often a chronic disorder when identified. It is
often comorbid with depression or other anxiety or physical health disorders, worsening the prognosis.
Rates of unemployment and social isolation are high, as GAD is associated with alcohol and substance
misuse in an attempt by patients to relieve symptoms. People with GAD have a high number of general
practitioner (GP) visits and secondary care contacts.
The most recent National Institute for Health and Care Excellence (NICE) guidelines established good
evidence for the effectiveness of low-intensity psychological interventions in GAD. Step 1 interventions are
usually delivered within primary care. If symptoms persist, referral to a step 2 low-intensity psychological
intervention is recommended, usually facilitated by a low-intensity Improving Access to Psychological
Therapies (IAPT) worker. However, a significant number of patients will not respond to these interventions
and require ‘stepping up’ to more intensive step 3 interventions. According to NICE guidelines, the choice at
step 3 is between a high-intensity psychological intervention [cognitive behavioural therapy (CBT)/applied
relaxation] and a drug treatment.
The NICE Guidelines Advisory Group proposed sertraline as a first-choice pharmacological treatment,
although it does not have a marketing authorisation for GAD and there are relatively few randomised
trials. Nevertheless, in terms of risk of discontinuation as a result of adverse effects, sertraline was the
best-tolerated antidepressant and its availability as a generic made it the most cost-effective choice.
There are a number of cognitive behavioural models of GAD. Dugas et al. (Dugas MJ, Gagnon F,
Ladouceur R, Freeston MH. Generalized anxiety disorder: a preliminary test of a conceptual model. Behav
Res Ther 1998;36:215–26) have developed a model known as the intolerance of uncertainty. This aims to
help affected individuals develop beliefs about uncertainty that are less negative, rigid and pervasive. It has
been tested in four published randomised clinical trials, with results indicating that it is more efficacious
than waiting list control, supportive therapy and applied relaxation. This CBT model was therefore selected
for this trial.
Although there is evidence of clinical effectiveness and cost-effectiveness of sertraline for GAD compared
with placebo, and also of CBT compared with waiting list controls, there have been no head-to-head
comparisons of sertraline [or any selective serotonin reuptake inhibitor (SSRI)] versus CBT to evaluate which
treatment is more clinically effective and cost-effective. Current NICE guidelines suggest that the choice of
treatment at step 3 between a pharmacological or psychological treatment should be based mainly on
patient preference.
Aims and objectives
When assessing effectiveness of CBT or SSRIs for GAD, assessment of both clinical symptoms and functional
impairment is important, as is assessment of outcomes for more than a few months, given that most
pharmacological studies have follow-up periods of ≤ 12 weeks, and there is some evidence that CBT may have
a protective effect against future episodes. Longer follow-up is crucial in making future recommendations,
as longer-term costs of prescriptions and of the use of health-care resources are required to evaluate relative
cost-effectiveness of the treatments. Our aim was to conduct a randomised controlled trial to compare the
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clinical effectiveness and cost-effectiveness of a pharmacological treatment (the SSRI sertraline) prescribed at
therapeutic doses, and a manualised psychological intervention (CBT) delivered by trained psychological
therapists to patients with persistent GAD that had not improved with low-intensity psychological interventions
as defined by NICE.
Hypothesis
We hypothesised that, in this population, CBT would lead to a greater improvement in GAD symptoms
as measured by the primary outcome the Hospital Anxiety and Depression Scale – Anxiety component
(HADS-A) at the 12-month follow-up than the prescription of sertraline in primary care in accordance with
recommended clinical guidelines.
Primary aim
To assess clinical effectiveness at 12 months of treatment with the SSRI sertraline compared with CBT for
patients with persistent GAD that had not improved with low-intensity psychological interventions.
Secondary aim
To calculate the cost-effectiveness at 12 months of treatment with sertraline compared with CBT for
patients with persistent GAD that had not improved with low-intensity psychological interventions.
Objectives of internal pilot
At the recommendation of the Health Technology Assessment (HTA) programme commissioning board,
we included a 12-month internal pilot with the following objectives:
1. to test and refine recruitment methods
2. to ascertain recruitment rates across pilot sites
3. to examine comorbidity between GAD, depression and other anxiety disorders
4. to ensure that the intervention could be delivered in accordance with the protocol in both arms
5. to monitor and assess follow-up rates of the completed primary outcome measure.
Methods
Recruitment was community based and linked with local IAPT services. We had four pilot sites, based in
London (Camden and Islington, with Kingston) and Greenwich, Bristol, and Coventry and Warwickshire.
If the internal pilot had been successful, we aimed to work with 15 sites across England in the full trial.
People not responding to step 2 low-intensity psychological interventions for their anxiety were reviewed
by their low-intensity IAPT workers [psychological well-being practitioners (PWPs)]. Those scoring ≥ 10 on
the Generalised Anxiety Disorder-7 (GAD-7) anxiety measure were given brief details about the trial and,
if interested in possibly taking part, their permission sought for contact by the research team. The team
offered them an assessment appointment and sent a full patient information sheet. With the patient’s
permission, their GP was contacted and asked to complete a Medical Suitability Review form to check that
the patient had no known medical contraindications to sertraline if randomised to that intervention.
At baseline assessment it was checked that participants had received and understood the information
sheet, and any queries had been answered. Informed consent was obtained before any trial procedures
were performed. If they were happy to proceed, inclusion and exclusion criteria were checked. The Mini
International Neuropsychiatric Interview (MINI) questionnaire was administered to check if participants
fulfilled Diagnostic and Statistical Manual of Mental Disorders 4th Edition (American Psychiatric
Association. Diagnostic and Statistical Manual of Mental Disorders 4th Edition. Washington, DC: American
Psychiatric Association; 2000) criteria for GAD. Other significant comorbid anxiety disorders were noted,
providing that the participant considered GAD their most important problem needing treatment, but
comorbid major depression was an exclusion factor.
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Inclusion criteria
l Age ≥ 18 years.
l Score of ≥ 10 on the GAD-7.
l Primary diagnosis of GAD diagnosed on the MINI questionnaire.
l Failure to respond to NICE-defined low-intensity interventions.
Exclusion criteria
l Inability to participate because of insufficient English or cognitive impairment.
l Current major depression.
l Comorbid anxiety disorder(s) causing greater distress.
l Significant dependence on alcohol or illicit drugs.
l Comorbid psychotic disorder.
l Receipt of antidepressants in the past 8 weeks or high-intensity psychological therapy within the past
6 months.
l Any contraindications to treatment with sertraline (including females of child-bearing potential
agreeing to a pregnancy test at the assessment).
If all eligibility criteria were fulfilled, the researcher administered the Hamilton Anxiety Rating Scale (HAM-A)
and asked the participant to complete baseline primary and secondary outcome measures. A copy of the
completed baseline assessment form was forwarded to the chief investigator to confirm eligibility and,
if confirmed, the participant was then randomised via an independent computerised service. The
randomisation outcome was transmitted electronically to the trial manager, who contacted participants
to inform them which treatment group they were in.
The research team also notified the patient’s GP to inform them of the treatment allocation. If randomised
to the medication arm, the patient was asked to make an appointment within the next 2 weeks to see
their GP to discuss starting treatment with sertraline. The research team gave the relevant local IAPT
services details of participants randomised to the CBT arm – the IAPT team then contacted the patient to
arrange a course of treatment.
Interventions
1. Pharmacological (SSRI sertraline): potential participants were informed that sertraline, although not
having current marketing authorisation for GAD, was recommended by NICE on the basis of its
effectiveness in GAD clinical trials and had agreed to be prescribed this if so randomised. Sertraline was
prescribed by the patient’s GP in accordance with recognised clinical guidelines. GPs were asked to
review these patients regularly (at least six times in 12 months) and patients were to take the
medication for 1 year unless they had significant adverse effects. The GPs were given details of the
suggested timing and content of these appointments with trial participants. The GP was asked to
record any adverse events and both participants and GPs were asked to report any serious adverse
events or suspected unexpected serious adverse reactions to the trial team.
2. Psychological (CBT): this was delivered by high-intensity therapists from local IAPT services trained to
deliver 14 (± 2) 50-minute sessions of a manualised treatment developed for use in GAD, covering six
treatment modules. A 2-day training course was provided for CBT therapists and their supervisors, and
the supervisors had monthly expert supervision from two of the trial co-applicants in addition to the
usual monthly clinical supervision given to the therapists. Procedures were agreed for a random 10% of
sessions to be independently rated and reviewed for competence and adherence by an external expert.
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Outcome measures
Primary outcome
The primary outcome was the HADS-A score at 12 months (this was a change from the original protocol
stipulating the GAD-7, as we were unable to ask for the GAD-7 not to be routinely collected at each
session in the CBT arm, which we had originally thought possible, and considered that this might be a
source of potential bias).
Secondary outcomes
Secondary outcomes included HADS-A score at 3, 6 and 9 months; HAM-A score at 12 months; GAD-7
score at 6 and 12 months (all anxiety measures); Patient Health Questionnaire-9 (depression) and EuroQol-5
Dimensions, three-level version (used in health economic analysis) scores at 3, 6, 9 and 12 months;
Work and Social Adjustment Scale score at 12 months (social functioning); Employment and Social Care
questionnaire score (health economics) at 6 and 12 months; Client Satisfaction Questionnaire score at 3
and 12 months; and a patient preference scale score at 12 months. We planned to collect health service use
data at baseline, for the preceding 6 months and at 12-month follow-up, recording GP consultations and
psychotropic drug prescriptions, secondary care attendances and IAPT CBT session attendances.
Sample size calculation
Following estimates indicating standard deviations (SDs) of between 4 and 5 for the change in HADS-A
scores between baseline and 12 months for both randomised conditions, we used an estimate of 5 for the
SD of our outcome measure, with an additional component of variance to give an intracluster correlation
coefficient of 0.02. With the conservative assumption of a cluster size of 7 and 20% for dropouts, we
needed a sample size of 360 patients to detect a (‘true’) average difference of 2 between treatments with
90% power at p < 0.05 (two-sided).
Analysis
Principal analyses would have been conducted in accordance with a prespecified statistical analysis plan,
finalised before database lock and conducted in accordance with the intention-to-treat principle using
generalised mixed models. In the economic analysis we planned to calculate the net monetary benefit
of CBT compared with sertraline for patients with persistent GAD who had not improved with step 2,
low-intensity psychological interventions.
Results
Actual versus anticipated recruitment
We anticipated slow recruitment in the first 3 months of the internal pilot, but expected that this would
improve as pilot sites became familiar with participant identification and recruitment processes. We had a
projected total recruitment of 90 participants over the 12-month internal pilot, based on previous local IAPT
data, with a target to achieve at least 70% (i.e. 63 participants at 1 year). Unfortunately, a very slow rate of
recruitment meant that 7 months into the internal pilot in January 2016 we had recruited only seven
participants as opposed to the projected 40, despite trying various strategies to improve recruitment rates.
Reasons for difficulties with recruitment
Fewer potential participants were identified by the PWPs than anticipated from our earlier IAPT data,
and of 60 potential participants identified at screening 45 declined to participate – the majority (n = 30)
because of reluctance to be randomised to receive medication. A further two were ineligible, two had GPs
who declined to participate and four were identified after the decision had been made to close the trial.
Many PWPs described their clients being very anxious about the uncertainty of being referred and allocated
to a random treatment. As a key component of GAD is worry about uncertainty, this is something we
probably underestimated and illustrates the potential difficulty of recruiting participants to a randomised
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxvi
controlled trial in GAD. Most potential participants identified were reluctant to consider randomisation to
medication, and recruitment via a psychological therapy service was almost certainly biased towards people
expecting to receive psychological therapy and therapists expecting to deliver this.
Strategies employed to improve recruitment
A number of methods were employed to attempt to improve identification of participants by PWPs.
These included circulating materials to help them keep study recruitment in mind, funding lead PWPs to
facilitate recruitment, meetings to discuss possible approaches to patients’ queries or concerns, and
database searches to identify possible cases both retrospectively and prospectively. Unfortunately, none of
these resulted in improved recruitment.
Health Technology Assessment monitoring meeting
Because of poor recruitment, the funders organised a monitoring meeting in January 2016 at which the
likely reasons were discussed and two possible further recruitment strategies presented: (1) a retrospective
search of GP databases to identify people with anxiety/depression in primary care who might have GAD and
could be approached about the trial; and (2) also identifying potential participants through a GP database
search, but then assessing suitable patients for eligibility to take part in the trial and randomisation to either
sertraline or high-intensity CBT within general practice without having to engage with a step 2 treatment
delivered by PWPs.
The HTA programme committee was unsure about option (1) as it was seen to be an approach that
would be unlikely to be generalisable within the NHS. Option (2), conducting the trial in primary care,
was considered viable but a significant deviation from the original commissioning brief, and it was thought
inequitable to proceed with this without reopening the application process. The decision was therefore
made to close the trial prematurely.
Conclusions and recommendations
Recruiting to a head-to-head trial of medication versus high-intensity psychological therapy does not appear
feasible in a psychological therapy service in which both patients and therapists are likely to be biased
towards psychological therapies. An alternative strategy would be to conduct the trial within primary care,
which is where initial choices are made between drug and psychological treatments. We would suggest that
the HTA programme consider this option that, although not fitting directly with the NICE stepped-care
model, fits more clearly with what generally happens in clinical practice.
Given the reluctance of patients to be randomised in this trial (both a reluctance to consider randomisation
to the medication arm, but also because of uncertainty associated with randomisation, which people with
GAD are likely to find particularly difficult) we would suggest that a naturalistic cohort patient-preference
design should be considered if randomisation is not possible within primary care.
Trial registration
This trial is registered as ISCRTN14845583.
Funding
Funding for this study was provided by the HTA programme of the National Institute for Health Research.
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Chapter 1 Introduction
Clinical background
Generalised anxiety disorder (GAD) is an anxiety disorder characterised by excessive, uncontrollable and
often irrational worry that interferes with daily functioning and can cause physical symptoms. People with
GAD often anticipate the worst and are very preoccupied with matters such as health issues, money,
death, interpersonal problems or work difficulties. Typical physical symptoms include fatigue, nausea,
muscle tension, palpitations or shortness of breath, difficulties concentrating and sleep difficulties, which
can lead to a misdiagnosis. These symptoms must be consistent and ongoing, persisting at least 6 months,
for a formal diagnosis of GAD to be made. The disorder often begins at an early age, and signs and
symptoms may develop more slowly than in other anxiety disorders.
Generalised anxiety disorder is common, with a prevalence of 4.7% in the 2007 English National Psychiatric
Morbidity Survey,1 but with lower rates of identification in primary care than expected.2 As symptoms have
to have been present at least 6 months before the diagnosis can be made, it is often a chronic disorder by
the time it is identified.3 It is often comorbid with depression or other anxiety or physical health disorders,
worsening the prognosis.4 In community samples, GAD is more common than depression,1 with higher
associated health and societal costs,5 but it has received much less attention, so establishing the most
effective treatments is crucial.
Generalised anxiety disorder is often associated with significant morbidity in terms of distressing psychological
and physical symptoms, and significant functional impairment.4 The degree of disability has been described as
similar to that in major depression or chronic physical illness.6 Rates of unemployment and social isolation are
high,4 as is concomitant alcohol and substance misuse in an attempt to alleviate symptoms.7 People with GAD
have high numbers of general practitioner (GP) visits and secondary care contacts, both because of associated
physical/somatic symptoms and because GAD is often comorbid with chronic physical health problems.8
The 2011 National Institute for Health and Care Excellence (NICE) guidelines entitled Generalised Anxiety
Disorder and Panic Disorder (With or Without Agoraphobia) in Adults: Management in Primary, Secondary
and Community Care9 established good evidence for the effectiveness of low-intensity psychological
interventions in GAD. Step 1 interventions are usually delivered within primary care, involving identification,
assessment, education and active GP monitoring. If symptoms persist, referral to a step 2 low-intensity
psychological intervention is recommended [e.g. self-help interventions or psychoeducation groups, usually
facilitated by a low-intensity Improving Access to Psychological Therapies (IAPT) psychological worker].10
However, a significant number of patients will not respond to these interventions and require ‘stepping up’
to more intensive step 3 interventions (Figure 1).
A substantial percentage of people with anxiety and/or depression referred to IAPT low-intensity workers still
have high Generalised Anxiety Disorder-7 (GAD-7) questionnaire scores after receiving a step 2 intervention,
indicating that they have not yet been effectively treated.11 GAD is also potentially a long-term, relapsing
condition. Thus, providing the most effective treatment, with a reduced likelihood of relapse, should provide
significant benefits in terms of both individual morbidity and accompanying health and social costs to
society, and was the focus of this study.
Existing research
The National Institute for Health and Care Excellence conducted a systematic review of placebo-controlled
antidepressant studies in GAD.9 Thirty-four studies were identified that were generally rated as being of
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high quality, although relatively short in duration (8–12 weeks). Of these trials, 17 involved selective
serotonin reuptake inhibitors (SSRIs), whereas 16 involved the serotonin–noradrenaline reuptake inhibitors
(SNRIs) venlafaxine and duloxetine. Both of the SNRIs, as well as the SSRIs paroxetine and escitalopram,
have marketing authorisations for the treatment of GAD. The NICE summary concluded that, relative to
placebo, SNRI and SSRI treatments were efficacious in the treatment of GAD in that they produced greater
reductions in Hamilton Anxiety Rating Scale (HAM-A) scores12 and increased the probability of patients
responding to treatment.
Generally, the effect sizes of antidepressants relative to placebo were in the low to moderate range and
did not apparently vary between the different antidepressants to a clinically meaningful extent.9 There was
no clear evidence of a dose–response relationship for any particular antidepressant, and the most
commonly experienced side effects were nausea and insomnia. These placebo-controlled studies were
generally not more than 12 weeks in duration, although GAD is considered to be a chronic disorder and
guidelines recommend the continuation of treatment in responders. A meta-analysis of available relapse
prevention studies suggested an important effect of continuing effective pharmacological treatment for up
to 1 year in patients with GAD who have responded to pharmacological therapy,13 although there is
currently no evidence that sertraline is effective in preventing relapse.14
Although there is evidence of the clinical effectiveness and cost-effectiveness of sertraline for GAD
compared with placebo, and also of cognitive behavioural therapy (CBT) compared with waiting list
controls,1 there have been no head-to-head comparisons of sertraline (or any other SSRI) versus CBT to
evaluate which treatment is the most clinically effective and cost-effective. Currently NICE guidelines
suggest that choice of treatment between a pharmacological or psychological treatment at step 3 should
be based mainly on patient preference, although availability of CBT may determine if patients have such a
choice in some areas.
In assessing the effectiveness of CBT or SSRIs for GAD, it is necessary to consider both clinical symptoms
and functional impairment. It is also important to assess outcomes of more than a few months, given that
most pharmacological studies do not have follow-ups of > 12 weeks9 and there is some limited evidence
that CBT may have a protective effect against future episodes.15 Longer follow-up is also crucial in making
future recommendations, as the longer-term costs of prescriptions and use of health-care resources
associated with each type of treatment are required to evaluate their relative cost-effectiveness.
STEP 3: GAD with an inadequate response to 
step 2 interventions or marked functional 
impairment
Choice of a high-intensity psychological 
intervention (cognitive–behavioural therapy/
applied relaxation) or a drug treatment
STEP 2: diagnosed GAD that has not improved
after education and active monitoring in
primary care
Low-intensity psychological interventions: 
pure self-help,a guided self-help and 
psychoeducational groups
STEP 4: complex treatment-refractory GAD
and very marked functional impairment, such
as self-neglect or a high risk of self-harm
Highly specialist treatment – for example 
complex drug and/or psychological treatment 
regimens or input from multiagency teams, 
crisis services, day hospitals or inpatient care
STEP 1: all known and suspected presentations
of GAD
Identification and assessment; education about
GAD and treatment options; active monitoring 
FIGURE 1 Stepped-care model for GAD. a, Pure self-help is defined as a self-administered intervention intended to
treat GAD and involves self-help materials (usually a book or workbook). It is similar to guided self-help but
without any contact with a health-care professional. Red font shows the step or choice of treatments that are
assessed in this trial.
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Following the updated NICE guidelines, there has been increased interest in GAD in the primary care
community, but uncertainty remains regarding whether pharmacological or psychological treatment is
indicated in more persistent cases.16 Clinicians can be reluctant to prescribe the SSRI sertraline, which,
although found by NICE to be the most cost-effective acute drug therapy for GAD, does not currently have
marketing authorisation for this use. Clear data regarding whether the SSRI sertraline or CBT is most
effective longer term in treatment of GAD, as well as further information about the safety and efficacy of
sertraline in this patient group, is of direct relevance to the NHS.
The NICE committee conducted a search for relevant updates to the 2010 guideline in 2012, but no relevant
trials adding to the literature were identified.17 The authors of this report have also conducted a further
rapid search of the literature to see if they could identify any relevant trials published between 2013 and
early 2016, but none was found. Most of the studies continue to evaluate the effect of either CBT or
medication for patients with GAD with no head-to-head comparison of a recommended psychological
treatment versus pharmacotherapy. One study by Crits-Christoph et al.18 combined treatment with
venlafaxine with 12 sessions of CBT for patients who wished to have this and found no added benefit from
the CBT at the 24-week follow-up, although the numbers in both groups were relatively small and those in
the venlafaxine-only group showed quite a marked benefit from this treatment.
The National Institute for Health and Care Excellence guidelines
research recommendation
The research recommendation from the NICE GAD Guidelines Group9 suggested the following: ‘A
comparison of the clinical and cost-effectiveness of sertraline and CBT in people with GAD that have not
responded to guided self-help and psycho-education’.
This recommendation suggested using a randomised controlled design in which people who had not
responded to low-intensity step 2 interventions for GAD would be allocated openly to one of three groups:
sertraline, CBT or waiting-list control for 12–16 weeks, with the control group being important to assess
whether or not the two active treatments would produce effects greater than that of natural remission. It
was suggested that follow-up assessments should be continued over the next 2 years to establish whether
or not any short-term benefits were maintained and whether or not either active treatment produces a
better long-term outcome.
Health Technology Assessment-commissioned research proposal
The research proposal commissioning brief published subsequently by the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) programme panel in 2013 was a little different, in
that it gave the following brief for the research question, omitting the third control arm to the trial and not
stipulating assessment after 12–16 weeks:
Is a selective serotonin reuptake inhibitor (SSRI) or cognitive behavioural therapy (CBT) more clinically
and cost-effective for patients with generalised anxiety disorder (GAD) who have not responded to low
intensity psychological interventions recommended in a stepped-care model?
Following from this, our final approved proposal was for a ‘Randomised controlled trial of the selective
serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy (CBT) for anxiety symptoms in
people with Generalised Anxiety Disorder (GAD) who have failed to respond to low intensity psychological
interventions as defined by the NICE GAD guidelines’, with the primary outcome being assessed at
12 months (see Chapter 2, Methods, for further details).
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Background to the choice of interventions to be assessed
Sertraline
The NICE Guidelines Advisory Group proposed sertraline as a first-choice pharmacological treatment, although
this agent does not have a marketing authorisation for GAD and there are relatively few randomised trials
(only two trials with 706 patients in total19,20).9 Nevertheless, in terms of risk of discontinuation because of
adverse effects, sertraline was the best tolerated antidepressant and was available as a generic brand, making
it the most cost-effective choice. Duloxetine (a SNRI) had a greater probability of producing clinical response in
a network meta-analysis, but this is not commonly prescribed in UK primary care. The SSRIs paroxetine and
escitalopram both have marketing authorisation for GAD, and there is little pharmacological difference
between them and the SSRI sertraline. However, paroxetine has a more marked withdrawal syndrome than
sertraline21 and escitalopram was still on patent and significantly more expensive at the time of submitting the
proposal. There are also more concerns about it extending the QT interval, although it is recognised that
sertraline can do this in vulnerable cases.22 In the two sertraline studies in GAD, sertraline was dosed flexibly
between 50 and 150 mg daily (mean dose at the end of treatment about 90mg). In one study sertraline was
started at 25mg daily for 1 week to improve tolerance early in therapy,23 and this acclimatisation period is also
recommended by the manufacturer in the licensed use of sertraline in post-traumatic stress disorder, social
anxiety disorder and panic disorder.24
Cognitive behavioural therapy
There are a number of cognitive behavioural models of GAD. Examples include the cognitive avoidance
model,25 the metacognitive model26 and the emotion dysregulation model.27 Dugas and Koerner28 have
also developed a model of GAD known as the intolerance of uncertainty model. Stated simply, the model
proposes that negative beliefs about uncertainty (or intolerance of uncertainty) lead to difficulty dealing
with real or imagined uncertainty-inducing situations, which can then lead to excessive worry and GAD.
Research has shown a consistent and robust relationship between intolerance of uncertainty and GAD;
for example, their relationship is not accounted for by shared variance with other anxiety disorders, mood
disorders or negative affect.29,30 Data also suggest that intolerance of uncertainty is a causal risk factor for
high levels of worry and GAD; for example, changes in intolerance of uncertainty precede changes in
worry over the course of treatment,31 and the experimental manipulation of intolerance of uncertainty
leads to corresponding changes in worry and monitoring behaviour.32,33 Thus, data from correlational,
longitudinal and experimental studies suggest that intolerance of uncertainty plays a key role in GAD.
The Dugas and Koerner model28 is one of three CBT protocols for GAD, which guides IAPT services in how
to carry out CBT effectively and in line with best practice. The treatment aims to help affected individuals
develop beliefs about uncertainty that are less negative, rigid and pervasive. This is accomplished with the
use of treatment strategies (such as behavioural exposure to uncertainty, problem-solving training and
imaginal exposure) that aim to help patients confront uncertainty-inducing thoughts and situations. The
treatment has been tested in four published randomised clinical trials, with results showing that it is more
efficacious than a waiting list control,34,35 supportive therapy36 and applied relaxation.37 The findings also
show that 60–77% of patients attain GAD remission and that 50–55% achieve high-end state functioning
following the treatment. The CBT protocol developed by Dugas and Robichaud (i.e. based on the
intolerance of uncertainty model of GAD) was therefore used in this trial.38
Time course of therapeutic effect and longer-term benefits
The planned comparison was between SSRI medication and CBT, which are both active treatments.
However, we considered that in a pragmatic trial the time course of benefit is likely to differ. The SSRI
medication might have a benefit earlier on, but it is likely that this effect could reduce over time, largely
because many of the participants may stop taking their medication. In contrast, CBT is an educational
approach that should be providing the participants with skills that they may use in the future. We would
therefore expect that CBT would continue to have benefit for the 12-month duration of the trial. As a result,
our hypothesis was that CBT would lead to a better outcome than SSRIs at the 12-month follow-up point.
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Chapter 2 Trial design: aims, objectives
and methods
This chapter details the aims, objectives and methods of the trial as originally planned and approved bythe funder, and subsequent modifications made as a result of discussions among the Trial Management
Group (TMG) and with the sponsor.
Summary of proposed research
The trial was entitled the ‘Randomised controlled trial of the SSRI sertraline versus CBT for anxiety
symptoms in people with GAD who have failed to respond to low-intensity psychological treatments as
defined by the NICE guidelines’. The trial acronym decided was ToSCA (Trial of Sertraline versus Cognitive
behaviour therapy for generalised Anxiety).
Overall aim
To conduct a randomised controlled trial (RCT) to compare the clinical effectiveness and cost-effectiveness
in terms of symptoms and function of a pharmacological treatment (the SSRI sertraline) prescribed at
therapeutic doses, with a manualised psychological intervention (CBT) delivered by trained psychological
therapists, to patients with persistent GAD that has not improved with low-intensity psychological
interventions as defined by NICE.
Hypothesis
Our hypothesis was that in people with GAD who had not responded to low-intensity psychological
interventions, as recommended by NICE, CBT would lead to a greater improvement in their GAD
symptoms as measured by the Hospital Anxiety and Depression Scale – Anxiety component (HADS-A)39
at the 12-month follow-up than prescription of the SSRI sertraline by their GP in accordance with
recommended clinical guidelines.
Primary aim
To assess the clinical effectiveness at 12 months of treatment with the SSRI sertraline compared with CBT
for patients with persistent GAD that has not improved with low-intensity psychological interventions.
Secondary aim
To calculate the cost-effectiveness at 12 months with the SSRI sertraline compared with CBT for patients
with persistent GAD that has not improved with low-intensity psychological interventions.
Detailed objectives
Internal pilot (first 12 months of the recruitment period)
1. To test and refine the recruitment methods for the main trial.
2. To ascertain recruitment rates across sites and the acceptability of the overall recruitment process.
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3. To examine the extent of comorbidity between GAD, depression and other anxiety disorders in the
population referred into the study.
4. To ensure that the intervention can be delivered in accordance with the protocol in both arms, with
satisfactory delivery of training and monitoring procedures.
5. To monitor and assess follow-up rates of the completed primary outcome measure (HADS-A) at 3 and
6 months within the pilot trial.
Overall trial (whole 24 months of the recruitment period including the internal pilot)
1. To recruit sufficient eligible patients with a Diagnostic and Statistical Manual of Mental Disorders-Fourth
Edition (DSM-IV)40 diagnosis of GAD willing to participate.
2. To compare the effect of high-quality, reproducible pharmacological and psychological interventions
delivered in accordance with clear criteria and evidence-based guidelines. We asked participating GPs
to follow established clinical guidelines for delivery of the pharmacological intervention, and the
psychological intervention was manualised and quality controlled.
3. To obtain high rates of follow-up data on a minimum of 80% of those recruited into this trial at
12 months in order to provide a definitive answer to the research question and assess the longer-term
outcomes of both interventions.
4. To analyse the results in accordance with the Consolidated Standards of Reporting Trials (CONSORT)
and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guidelines.
5. To disseminate the outcomes to the NHS, academic colleagues, relevant service user groups and the
wider community.
Methods
Setting
The study was community based and linked with local IAPT services.10 We aimed to work with five
recruitment sites in southern England during the pilot phase and up to 15 sites across the whole of
England in the full trial.
Recruitment of participants
People who had not responded to step 2 low-intensity psychological interventions for anxiety or depression
who were being considered for step 3 interventions within their local IAPT services were considered eligible
(Box 1 contains a list of step 2 low-intensity interventions meeting the inclusion criteria). Identification was
by low-intensity IAPT workers, who routinely administer the GAD-7 anxiety measure41 and Patient Health
Questionnaire-9 (PHQ-9) depression measure,42 reviewing patients. Those patients scoring ≥ 10 on the
GAD-7 were given brief details about the trial and if they were interested in finding out more, and possibly
taking part, their permission was sought for contact by the research team. If they were unsure about their
interest at this stage they were given a brief flyer about the aims of the trial and invited to contact the
research team for more information or to discuss things further.
The central research team (trial manager/research assistant) were faxed the details of those who had
agreed to be contacted by the research team and aimed to respond within 1 week (preferably by
telephone or e-mail or, if not, by letter) offering them an appointment at the IAPT premises or their own
home, whichever was preferred. A full study information sheet was sent to potential participants at this
stage (see Appendix 1) and the patient’s GP was contacted, with their permission, and asked to complete
a Medical Suitability Review form to check that there were no known medical contraindications to them
being prescribed sertraline if they were randomised to that intervention arm in the trial (see Appendix 2).
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Recruitment appointment/baseline assessment
The baseline interviews and assessments were conducted by a member of the central or local research
team (research assistant or clinical studies officer). They checked, at the outset, that potential participants
had read and understood the study information leaflet, and answered any queries. They also checked that
the patient understood the reasons for the study and confirmed at that point that they were interested in
taking part on the understanding that, if randomised to the drug arm, they would receive the SSRI
sertraline that, although proposed for use outwith a marketing authorisation for GAD, was recommended
by NICE on the basis of its clinical effectiveness and cost-effectiveness in randomised trials. They also
ensured prior to the appointment that there were no medical contraindications to receiving the medication
sertraline recorded on the Medical Suitability Review form as returned by the GP (see Recruitment of
participants, above).
Those agreeing to take part were asked to give fully informed consent before undergoing the eligibility
check and baseline assessment. It was expected that most patients would be willing to consent to the
study at the baseline visit, but if they were unsure they could be rescheduled for consent and baseline
assessment at a later date. The assessment was conducted at the IAPT site or GP surgery in accordance
with patient preference. Written consent was obtained by a delegated and appropriately trained member
of staff. No clinical trial procedures, including confirmation of eligibility, were conducted prior to taking
consent. A copy of the consent form was given to the patient, the original retained in the investigator site
file and a further copy sent to the patient’s GP for their medical notes (see Appendix 3).
BOX 1 ToSCA: included and excluded low-intensity step 2 interventions
A key inclusion criterion for the study is that patients should have received an initial low-intensity intervention
but still have above-threshold symptoms (GAD-7 score of ≥ 10). Set out below are the types of low-intensity
intervention (and the minimum number of sessions for each) that meet this inclusion criterion and also some
excluded interventions.
Included interventions
l Guided self-help carried out by a PWP or equivalent low-intensity worker: patient needs to have had at
least two treatment sessions after initial assessment session.
l Pure self-help (non-facilitated self-help): patient needs to have had at least one follow-up session after the
self-help resource was recommended.
l cCBT: patient needs to have logged on and completed at least two cCBT sessions.
l Psychoeducational or similar group facilitated by a PWP or equivalent low-intensity worker: patient needs to
have attended at least two sessions of the group.
l Exercise intervention if the exercise is for mood/anxiety: patient needs to have tried the recommended
exercise intervention at least twice.
l One-off workshop lasting at least half a day, facilitated by a PWP or equivalent low-intensity worker.
Excluded interventions
l Signposting interventions (signposting to other services).
l Guided self-help carried out by a qualified (or trainee) CBT therapist or other high-intensity therapist.
l Psychoeducational or similar group, or one-off workshop facilitated by a qualified (or trainee) CBT therapist
or other high-intensity therapist.
cCBT, computerised cognitive behavioural therapy; PWP, psychological well-being practitioner.
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If potential participants were happy to proceed, then the inclusion and exclusion criteria were checked
(see Inclusion criteria and Exclusion criteria), which included administering a pregnancy test to females of
child-bearing potential. In assessing whether or not the potential participant fulfilled the DSM-IV criteria
for GAD, the relevant sections of the Mini International Neuropsychiatric Interview (MINI) questionnaire43
were administered by the research team member (depression, panic, social anxiety, alcohol and substance
misuse, and GAD). If the DSM-IV criteria for GAD were fulfilled, potential participants were asked to
confirm whether their GAD or worry symptoms were more severe and of more concern to them than any
symptoms that they might have associated with psychological comorbidities, such as depression and other
anxiety disorders, and that this was an important problem for them that they wanted to address.
If they fulfilled this criterion and all the other eligibility criteria, the researcher then administered the
HAM-A questionnaire12 and asked the participant to complete the primary and secondary outcome
measures at baseline, aiming for 100% completion of measures at baseline (see Outcome measures).
Inclusion criteria
l Age ≥ 18 years.
l Positive score of ≥ 10 on the GAD-7.
l Primary diagnosis of GAD as diagnosed on the MINI.
l Failure to respond to NICE-defined low-intensity interventions.
Exclusion criteria
Exclusion criteria were expanded from those in the initial approved protocol after discussion with the
sponsor [University College London (UCL) Joint Research Office (JRO)].
l Inability to complete questionnaires because of insufficient English or cognitive impairment.
l Current major depression.
l Other comorbid anxiety disorder(s) of more severity or distress to the participant than their GAD.
l Significant dependence on alcohol or illicit drugs.
l Comorbid psychotic disorder, bipolar disorder.
l Treatment with antidepressants in past 8 weeks or any high-intensity psychological therapy within past
6 months.
l Currently on contraindicated medication: monoamine oxidase inhibitors within the past 14 days
or pimozide.
l Patients with poorly controlled epilepsy.
l Known allergies to the investigational medicinal product or excipients.
l Concurrent enrolment in another investigational medicinal product trial.
l Severe hepatic impairment.
l Women who are currently pregnant or planning pregnancy, or lactating.
l Patients on anticoagulants.
l History of bleeding disorders.
Randomisation and notification of general practitioner and cognitive
behavioural therapists
A copy of the completed baseline assessment form was forwarded by the researcher to the chief
investigator (CI) or delegated clinician in order to confirm participant eligibility. After confirming eligibility,
the CI or delegated clinician accessed a web-based interface using a unique username and password, and
entered the unique study identification number for the participant in order to randomise them to one of the
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two intervention arms via an independent computerised service (Sealed Envelope Ltd, London, UK) provided
by the PRIMENT Clinical Trials Unit (CTU). There were no stratification variables. The randomisation outcome
was transmitted electronically to the trial manager who then contacted the individual participants within
2 working days of their baseline assessment to inform them of which treatment group they were in.
The research team (trial manager or research assistant) ensured that the patient’s GP was notified about
their patient being enrolled in the trial and which treatment arm they were in. They were also notified if
the patient was not eligible for inclusion in the trial (see Appendix 4).
If they had been randomised to the medication/sertraline arm, the patient was asked to make an
appointment within the next 2 weeks to see their GP to discuss starting the treatment, and the research
team let their GP know that they would be doing this (see Appendix 5).
The research team also gave the relevant local IAPT services the details of participants randomised to the
CBT arm – the IAPT team then contacted the patient to arrange a course of treatment.
Interventions
Pharmacological intervention: sertraline
The medication sertraline was prescribed by the patient’s GP in accordance with recognised clinical
guidelines. The GPs were asked to review these patients regularly (at least six times in 12 months) and
patients were to take the medication for 1 year unless they had significant adverse effects. The GPs were
given details of the suggested timing and content of each of these appointments with the trial participants
(see Appendix 6).
The GP was to act in the best interests of the participant at all times, so was free to refer them to
secondary care services or psychological treatments if indicated. We explained that we would prefer
patients in the SSRI arm not to be referred to or receive CBT while in the trial, but appreciated this might
occasionally happen and should be documented in their GP notes.
If the patient made any interim visits to the surgery to discuss their treatment for GAD or issues to do with
the medication being received, we asked for these to be clearly documented in their notes (we costed for
up to four additional visits per GP to cover this possibility).
The GP was asked to record any adverse events and both the participants and their GPs were asked to
report any serious adverse events (SAEs) or suspected unexpected serious adverse reactions (SUSARs) to
the trial team (see Appendix 7).
Psychological intervention: cognitive behavioural therapy
This was delivered by high-intensity therapists from local IAPT services who were trained to deliver 14 (± 2)
50-minute sessions of a manualised treatment developed for use in GAD.
This covered six treatment modules:
1. Psychoeducation and worry awareness training – the first few sessions of treatment are devoted to
psychoeducation in which patients begin to monitor their worrying on a day-to-day basis, and learn
to distinguish between worries about current problems and worries about hypothetical situations.
2. Re-evaluation of the usefulness of worry – patients identify and re-evaluate their positive beliefs about
worry using strategies such as role-play and hypothesis testing. Patients are helped recognise that their
beliefs about the usefulness of worry are interpretations and not facts, and begin the process of
‘imagining a life without worry’.
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3. Uncertainty recognition and behavioural exposure – participants learn that intolerance of uncertainty
contributes to worry and anxiety, and that uncertainty-inducing situations are largely unavoidable.
They then learn to seek out and experience uncertainty-inducing situations.
4. Problem-solving training – for worries about current problems, participants learn to use a problem-
solving procedure targeting problem orientation, problem definition and goal formulation, generation
of alternative solutions, decision-making, and solution implementation and verification.44
5. Written exposure – in the field of health psychology, a method known as written emotional disclosure
has been shown to lead to positive health outcomes.45 Written exposure sessions are continued until
writing about the feared outcome no longer provokes anxiety (typically 8–10 exposure sessions).
6. Relapse prevention – the final component is relapse prevention, the aim of which is to consolidate the
attitudes, beliefs and skills acquired during therapy. Patients are encouraged to continue practising their
new skills and prepare for stressors that may arise.
Sessions were to be digitally recorded and a random 10% to be assessed for quality (fidelity to the
manual and therapist competence) by an independent external assessor according to prespecified criteria
(see Chapter 6 for further details).
Usual care by general practitioner
Randomisation was between sertraline prescribed by the participant’s GP and CBT provided within an
IAPT service, and both interventions were to be in addition to any other usual care provided by the GP.
As always, the patients could be offered other medication or psychotherapy as part of their usual care,
although we encouraged the GPs not to change the patient’s medication unless clinically indicated or
requested by the patient, and not to refer them for CBT while in the sertraline arm if possible. Usual
practice would be to allow the patient with GAD to choose, with the help of their GP, between a SSRI and
CBT if they met the criteria for a step 3 intervention and if neither was contraindicated.
Patients in the CBT arm were likely to receive their CBT treatment more quickly than is usual in most NHS
settings, and it was a psychological intervention specifically developed for people with GAD that is not
current UK practice. NHS waiting lists mean that patients in the SSRI arm who then asked to be referred
for CBT were likely to experience significant delays in receiving this. We proposed to record and measure
all use of antidepressants and other forms of counselling or psychotherapy, whether NHS or private, and to
take account of these in the analysis.
Outcome measures
The outcome measures to be collected during the trial are summarised in Table 1, according to the time at
which each would be collected.
Primary outcome
The primary outcome was the HADS-A measured at 12 months. This is the 7-item anxiety component of
the Hospital Anxiety and Depression Scale, a very widely used 14-item scale that can be self-administered.
It has high validity and reliability, and the anxiety and depression components have been assessed
separately as primary outcomes.39
The primary outcome measure was initially the GAD-7,41 but this was changed to the HADS-A about
6 months after the study had started and before the recruitment of any trial participants had begun.
This was done because we had originally understood, when selecting the GAD-7 as our primary outcome
measure for both intervention arms, that it would be possible to ask participants seeing IAPT high-intensity
therapists for treatment in the CBT intervention arm not to complete the GAD-7 questionnaire at every
CBT session, which is IAPT’s current usual practice. Unfortunately, it was not possible to negotiate this in
all the pilot study areas. As a result of this we were concerned that using the GAD-7 in the trial as the
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primary variable when this is associated with treatment in one of the groups (i.e. the CBT group) was a
source of potential bias, and we therefore decided to change the primary outcome measure to the
HADS-A.
Secondary outcomes
These were all self-completed measures to be collected by postal questionnaire, apart from the
researcher-administered MINI and health service outcomes collected from patient notes.
l HADS-A: the HADS-A was collected at baseline and then as a secondary outcome measure at 3, 6 and
9 months.39
l HAM-A: this is a 14-item observer-rated anxiety scale, which has been widely used, particularly in
pharmacological studies.12 It was to be administered by a member of the research team at baseline and
at the 12-month follow-up.
l GAD-7: a 7-item self-completion questionnaire with very good sensitivity (89%) and specificity (82%)
for GAD.41 It is one of the core measures regularly administered by the IAPT services.10 It was to be
collected at baseline, and at 6 and 12 months.
l PHQ-9: this is a 9-item self-rate scale widely used to monitor the severity of depression.41 It was to
be collected every 3 months for the 12-month duration of the study, along with the HADS-A and
EuroQol-5 Dimensions, three-level version (EQ-5D-3L).
l Work and Social Adjustment Scale (WSAS): this is a 5-item self-completion questionnaire that we
planned to use to assess participants’ difficulties with physical and social functioning.46 It was to be
collected at baseline and at the 12-month follow-up.
l EQ-5D-3L: a 5-item self-completion measure used to assess quality of life and calculate utility scores for
quality-adjusted life-years (QALYs).47 It was to be collected every 3 months for the 12-month duration
of the study, along with the HADS-A and PHQ-9.
TABLE 1 Summary of study assessments
Assessment/measure
Time point (months)
0 3 6 9 12
Informed consent ✓
Establishing eligibility ✓
Randomisation ✓
Urine pregnancy test ✓
MINI (relevant sections) ✓ ✓
HADS-A ✓ ✓ ✓ ✓ ✓
GAD-7 ✓ ✓ ✓
HAM-A ✓ ✓
PHQ-9 ✓ ✓ ✓ ✓ ✓
WSAS ✓ ✓
EuroQol-5 Dimensions ✓ ✓ ✓ ✓ ✓
Health economics questionnaire: ESC questionnaire ✓ ✓ ✓
Patient preference rating scale ✓ ✓
Treatment acceptability scale: Client Satisfaction Questionnaire ✓ ✓
Health service outcomes ✓ ✓
ESC, Employment and Social Care; WSAS, Work and Social Adjustment Scale.
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l Employment and Social Care questionnaire (ESC): relevant data on services used and productivity losses
were to be collected using this modified version of the Client Service Receipt Inventory48 at baseline,
and at the 6- and 12-month follow-up.
l Patient acceptability measure: we planned to use the Client Satisfaction Questionnaire (CSQ), a brief
8-item self-completion questionnaire administered at 3 and 12 months.49
l Patient preference rating scale: we planned to use a Likert scale used by our team in other studies,
also administered at baseline and at the 12-month follow-up.
l MINI:43 it was an addition to the original protocol to also administer the MINI questionnaire at the
12-month follow-up to assess the depression, panic, social anxiety and GAD components, with the
intention of establishing whether or not the participant met the criteria at follow-up for DSM-IV
caseness for GAD or any of the common psychological comorbidities.
l Health service outcomes: we planned to collect health service use data from both intervention arms at
baseline, capturing health service use for the preceding 6 months, and again at 12-month follow-up
for the following items of health service use during the preceding 12 months: total GP consultations as
well as those coded for GAD, psychotropic drug prescriptions from the GP surgeries, and secondary
care attendances including mental health and psychological services. The IAPT sites agreed to inform
the research team of the attendance rates for CBT sessions attended by trial participants in the CBT
intervention arm.
l Serious Adverse Events Monitoring Form: we planned to use the standard SAE template provided by
the PRIMENT CTU, modified for use in this study.
Final assessment at 12 months
A member of the research team would have administered the HAM-A face to face to all participants at
12 months and encouraged them to complete the 12-month outcome measures at this point to ensure
optimum data collection. This would have involved a different member of the research team from the
original assessor, who would have been blind to the participant’s trial allocation. As a check on this, they
would have been asked to say which trial arm each participant they assessed had been randomised into.
Procedures for reporting and recording serious adverse events
Patients were asked at each GP visit about side effects or health issues occurring while on medication, as is
normal clinical practice, and both the patients and GPs were asked to let the study team know about any
serious medical problems that may have occurred between consultations or be reported at the time of the
medication review. All patients recruited to the study were given a card with details of how to contact the
central research team about any serious medical problems occurring while they were in the trial at the time
that they were informed about the outcome of the randomisation procedure. The same applied to both
the GPs and IAPT CBT intervention therapists, who were given a brief explanatory sheet indicating when
they should be informing the research team about any serious medical problem affecting a participant in
the trial (see Appendix 7).
Both the GPs and the IAPT therapists were asked to notify the CI about any serious medical problems
(to cover SAEs, SUSARs or important medical events) that might affect any participant in the trial as soon
as they were aware of this. The CI or an appropriate delegated member of staff would then be asked to
complete the sponsor’s SAE form and to e-mail this to the PRIMENT CTU on behalf of the sponsor within
24 hours of his/her becoming aware of the event. The CI was expected to respond to any SAE queries
raised by PRIMENT CTU as soon as possible. All SAEs were to be recorded in the relevant case report form
and the sponsor’s adverse event log, which was to be reportable to the sponsor once per year.
The CI or delegate might also contact the patient’s GP, depending on the nature of the SAE, to obtain
more information regarding the adverse event. All SUSARs were to be notified to the sponsor within
24 hours according to the sponsor’s written standard operating procedure.
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Sample size calculation
The principal outcome variable is the change from baseline to 12 months in the HADS-A score which we
planned to compare between treatment groups in a regression model that accounted for baseline scores.
Tests and confidence intervals for treatment effects would be based on the normal distribution – an
assumption justified by the central limit theorem. Estimates for the standard deviation (SD) of HADS-A
scores are available from Tyrer et al.50 In this study, SDs between 4 and 5 were found for the change of
score between baseline and 12 months for both randomised conditions. Therefore, we used an estimate
of 5 for the SD of our outcome measure, overlaid with an additional component of variance (essentially
attributable to the therapist) sufficient to give an intracluster correlation coefficient of 0.02. Then, making
the conservative assumption of a cluster size of 7 and an allowance of 20% for dropout and other
challenges, this meant we would require a total sample size of 360 patients to detect a (‘true’) average
difference of 2 between treatments with 90% power at p < 0.05 (two-sided). Furthermore, the expected
half-width of the 95% confidence interval for the treatment difference is then 1.2.
With this sample size, we would have retained ≥ 80% power should the intraclass correlation coefficient
turn out to be 0.05 rather than 0.02. Alternatively, we would retain 80% power should the SD of our
outcome measure turn out to be 5.8 rather than 5. This design had the advantage of providing robust
interpretation in a number of circumstances as a result of the planned precision. Thus, with no impact on
alpha spending, it would be possible to interpret a significant difference between the groups of > 2 points
as also being clinically relevant and, additionally, a non-significant result that excludes a difference of 2
points (i.e. the upper confidence interval range < 2 points) as demonstrating non-inferiority. Furthermore,
a non-significant difference in which the outer bands of the confidence interval are < 2 points on the
HADS-A would indicate equivalence. The planned precision of the trial is such that it should have provided
a firm basis for decision-making even if opinions as to the correct size of the minimally important
difference were to have altered somewhat before the results became available.
Statistical analysis plan
Summary of baseline data and flow of patients
We planned to follow the CONSORT guidelines in reporting and analysing our data. This included
presenting a table of summary statistics for those secondary outcome variables collected at baseline showing
clinical characteristics for each group along with (baseline) demographic characteristics. We also planned to
create a flow chart that would provide the number of potential participants who were screened, eligible,
randomised and followed up at each time point.
Primary outcome analysis
The principal outcome variable was the change from baseline to 12 months in the HADS-A score, which we
aimed to compare between treatment groups in a regression model that accounted for baseline scores. Tests
and confidence intervals for treatment effects would be based on the normal distribution – an assumption
justified by the central limit theorem. Given that there is a single primary outcome, no corrections for multiple
comparisons would be required for the statistical inference. The principal analyses would have been conducted
according to a prespecified statistical analysis plan to be finalised before database lock. The principal analyses
would have been conducted according to the intention-to-treat principle using generalised mixed models.
The primary analysis would have used a generalised mixed model accounting for clustering of therapist effects,
investigational sites (both as random effects) and a limited number of prespecified patient-level factors,
including baseline HADS-A score. The principal analyses would have been based on available data, and
supportive analyses would examine the extent to which the principal analyses are robust to the challenge
presented by the observed loss to follow-up. Exploratory analyses would have been carried out to describe
how patient preferences along with a limited number of other prespecified characteristics of participants may
modify treatment effects.50 Any subgroup analyses conducted would also have been regarded as exploratory.
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Secondary outcome analysis
The secondary outcome variables would have been analysed using the same (generalised mixed model)
framework as for the primary outcome variable. However, the presentation of the results would have been
restricted to the confidence intervals that come out of the analysis, rather than the p-values.
Economic evaluation
We planned to calculate the net monetary benefit (NMB) of CBT compared with sertraline for patients with
persistent GAD who had not improved with step 2 low-intensity psychological interventions. A higher NMB
indicates greater relative cost-effectiveness. Health- and social-care resource use would have been collected
for both interventions over the 12-month duration of the trial using patient GP records, and patients asked
to complete a significantly reduced version of the Client Service Receipt Inventory (the Employment and
Social Care questionnaire) at baseline and 12 months. The health service resource use data collected
would have focused mostly on primary care and psychological therapies. Details of secondary care and
mental health resource use would also have been collected. Health-care resource use for the preceding
6 months would have been collected at baseline for adjustment purposes only. Resource use would be
multiplied by costs from nationally published sources and summed to calculate the total cost per patient.
The health-care resource use associated with the interventions would have been captured in each arm as
follows: the cost of sertraline and any follow-up, training or monitoring costs; the cost of CBT based on
the number of sessions attended per patient, session duration, the staff type and grade delivering the CBT;
and training and any overhead costs.
The mean cost per patient for patients in the sertraline and CBT groups would have been calculated and
confidence intervals reported, calculated using non-parametric bootstrapping with replacement and
adjusting for baseline service use. The mean QALYs per patient would have been calculated from the
EQ-5D-3L51 and the UK algorithm for calculating utility scores.52 The EQ-5D-3L would have been collected
at baseline, 3, 6, 9 and 12 months to allow calculation of the area under the curve over the 12-month trial
duration for the SSRI and CBT groups, adjusting for baseline differences. The NMB of both interventions
would have been calculated for a range of values of willingness to pay for a QALY. Confidence intervals
would have been constructed using non-parametric bootstrapping. A cost-effectiveness acceptability
curve would have been used to report the probability that each intervention has the higher NMB for a
range of values of willingness to pay for a QALY. One-, two- and multiway sensitivity analyses would have
been conducted for any assumptions made. Missing data and clustering would have been handled as
specified in the statistical analysis plan.
Sensitivity and other planned analyses
The principal analyses would have been conducted according to a prespecified statistical analysis plan, to
be finalised before database lock. The principal analyses would have been based on available data and
supportive analyses would have examined the extent to which the principal analyses were robust to the
challenge presented by the observed loss to follow-up. Exploratory analyses would have been carried out
to describe how patient preferences, along with a limited number of other prespecified characteristics of
participants, might modify treatment effects.
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Chapter 3 Obtaining ethics and research
governance approvals
Timetable: sponsor and Medicines and Healthcare products Regulatory
Agency approvals
The official start date of the trial as agreed with the NIHR’s HTA programme was 1 August 2014.
This was a clinical trial of an investigational medicinal product, and we started working with the sponsor
(the UCL JRO) before the official start date on the sponsorship procedures required. After several iterations
the JRO approved the first version of the trial protocol on 5 November 2014 (protocol number 14/0249).
Application for clinical trials authorisation was made to the Medicines and Healthcare products Regulatory
Agency (MHRA) on 7 November 2014 and their approval was received on 13 November 2014.
Ethics approval and major amendments
Our local Research Ethics Committee (REC) was Brent National Research Ethics Service Committee
London, and the relevant Integrated Research Application System application was submitted to them on
7 November 2014 and presented at a meeting of the REC on 24 November 2014.
We received a favourable ethics opinion, with conditions, on 3 December 2014 and gained full approval
on 9 December (REC reference number 14/LO/2105).
l Major amendment 1: at the TMG on 21 January 2015 a major protocol amendment altering the
primary outcome measure from the GAD-7 to the HADS-A was suggested (see Chapter 2, Methods).
This was developed and agreed with the NIHR’s HTA programme and Trial Steering Committee (TSC)
before being submitted to the REC and MHRA on 9 March 2015. There were also some minor study
document changes submitted with this major amendment request. Approvals were obtained from the
REC on 17 March 2015 and from the MHRA on 10 April 2015.
l Major amendment 2: a further major amendment was submitted on 13 April 2015 listing the four pilot
sites for the trial and giving details of their principal investigators (PIs). This was approved by the REC
on 23 April 2015.
l Major amendment 3: a third major amendment was submitted on 23 July 2015 applying to change the
named PI at the Bristol site and was approved on 30 July 2015.
l Major amendment 4: the final major amendment was for approval for a 6-month replacement of the
CI Dr Marta Buszewicz by Professor Irwin Nazareth, this amendment was submitted on 16 September
2015 and approved on 1 October 2015.
Research governance
Obtaining research governance permission proved more complicated and led to a significant delay in being
able to start the trial. It was confirmed that we had submitted a full set of documents for study-wide
approval on 27 January 2015, but significant delays followed while our lead Clinical Research Network
(CRN) queried the governance arrangements for participating GP practices and whether or not they should
be registered as individual research sites, which would have been very administratively burdensome,
given that most of the planned 360 trial participants were likely to be registered at different practices.
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We worked with the CRN and the Health Research Authority to develop the documents required for a
generic site-specific information form, which allowed us to obtain NHS approval for the collection of health
service usage data for trial participants from their GP notes without registering each general practice as a
research site. This was approved by the national NIHR Coordinated System for gaining NHS Permissions
(NIHR CSP) co-ordinating centre on 14 April 2015 and we finally received study-wide research and
development (R&D) approval on 27 April 2015 – 3 months after initial submission of the full set of
documents (see Appendix 8).
Having received national approval on 14 April 2015, it then took several further months to receive local
assurances for all the pilot sites – the last of these was the South London assurance for Kingston and
Greenwich received on 3 July 2015.
Sponsor documentation prior to site set-up visits
From February to May 2015 the trial team worked with the PRIMENT CTU on the final documentation
required for the trial management file and site files prior to the site initiation visits. This included the trial
monitoring plan, trial pharmacovigilance documents and training procedures, and a formal agreement
between the PRIMENT CTU and the CI because a large number of sponsor responsibilities were being
delegated to the CTU.
Trial database and electronic case report form development
The trial team worked over the same period with the CTU data manager and database developer to
finalise the data management plan, trial database and electronic case report forms for the study. Rigorous
database testing was carried out and sign-off achieved on 25 June 2015.
Monitoring processes
The PRIMENT CTU led on developing the monitoring plan. The trial monitor was John Codington of Cod
Clinical Ltd, an external monitor with whom the CTU had previously worked.
The plan was for the central research site at UCL to receive a monitoring visit 3 months after being opened
and for the first monitoring visit following initiation for the IAPT pilot sites to take place after five patients
had been randomised at each site. Further on-site monitoring visits were to take place annually at each site.
In the event, because of very poor recruitment no monitoring visits took place.
University College London data safe haven
We worked with the UCL Information and Services Division to set up a secure storage system for any
confidential data on the UCL Data Safe Haven system, although in the event we did not need to store any
data there given the lack of participant recruitment and early termination of the trial.
This service provides a technical solution for storing, handling and analysing identifiable data. It has
been certified to the ISO27001 information security standard53 and conforms to the NHS Information
Governance Toolkit.54 Built using a walled garden approach, in which the data are stored, processed and
managed within the security of the system, it avoids the complexity of assured end-point encryption. A file
transfer mechanism enables information to be transferred into the walled garden simply and securely.
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Chapter 4 Conduct of the trial: anticipated
recruitment rate, Improving Access to Psychological
Therapies and research staff training, and pilot
site openings
Anticipated recruitment rate
To date, there have been few large-scale trials recruiting from IAPT services, and none to our knowledge
that have recruited from the caseloads of low-intensity IAPT staff or that have compared psychological
interventions with medication. Three of the co-applicants (JC, MS and RS) have experience of working with
IAPT services as researchers, trainers and service leads. They arranged contacts between the research team
and IAPT study sites to ensure local understanding of recruitment procedures and assist in troubleshooting
problems, as well as arranging training and supervision of the high-intensity CBT therapists involved in
delivering the intervention (see Chapter 6 for details of the training and supervision of the high-intensity
CBT therapists).
Prior to writing the proposal we examined the IAPT data for the year 2011–12 for two local London
boroughs with a combined population of 426,000 during the year (Camden and Islington), among which
6569 people had an initial appointment within their IAPT services. Of these, 694 people (11%) were
initially seen by an IAPT low-intensity therapist and were stepped up from a low- to high-intensity
intervention with a GAD-7 score of ≥ 10. Eighty-nine (13%) of these 694 people were given a provisional
primary diagnosis of GAD by the low-intensity worker and would have been potential candidates for our
trial. Sixty-nine per cent were given other provisional primary diagnoses, and for 18% no diagnostic coding
was made. We assumed that 67% of those with a GAD-7 score of ≥ 10 and suitable to be stepped up
would be on antidepressants already or decline to be randomised. Extrapolating from the 89 people with a
provisional primary diagnosis of GAD, this would have excluded 60, leaving 29 suitable and potentially
willing to be randomised for the study.
As low-intensity IAPT staff have minimal training in making psychiatric diagnoses, we were conscious that
a recruitment strategy that relied on them identifying people with GAD would be likely to miss many
suitable people with GAD. This would include people with GAD comorbid with other anxiety disorders
and with depression, pure GAD being rare compared with comorbid GAD. Accordingly, our recruitment
strategy would need to encourage low-intensity IAPT staff to identify people as suitable for the study if
there was a possibility they might have GAD, including comorbid with depression and other types of
anxiety. So, in terms of the numbers identified in our two local London boroughs above, we wanted not
just the 89 people with a GAD-7 score of ≥ 10 for whom they gave a provisional diagnosis of GAD, but all
694 people with a GAD-7 score of ≥ 10 to be considered if there was a possibility they might have GAD.
We assumed that if this broader identification approach was adopted, a much larger pool of potential
participants would be identified and referred for baseline assessment by the low-intensity workers,
although up to half of the patients assessed for the study might then be ineligible because of a comorbid
major depressive disorder or because the patient identified another anxiety disorder as being more
significant than their GAD.
In order to recruit sufficient people for this trial, we needed to recruit a total of 360 people (see Chapter 2,
Sample size calculation), which equated to 24 participants per study site if there were 15 sites. This would
have meant recruiting one participant per site per month over the full 24 months of the trial period, or two
participants per month over a 12-month period.
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During our internal pilot phase we worked on forming relationships with the local low-intensity IAPT
workers during the initial 3 months and ensuring that they were committed and clear as to what was
required. We then aimed to recruit two participants per month from each of the five pilot sites for the
succeeding 9 months, resulting in a total planned recruitment of 90 participants during this pilot phase
(i.e. 25% of our planned total recruitment of 360 participants). We also planned to consolidate our relationships
with a further 10–15 sites throughout England during this time, so that we were in a good position to
recruit the remaining 170 participants over the following 12 months of the main trial recruitment period.
Our assumptions regarding the number of patients to be screened and recruited across the 24 months of
the whole trial are outlined in Figure 2 and the number of patients we planned to recruit at each of the
pilot sites during the 12 months of the internal pilot is given in Table 2. The pilot sites would continue
recruiting and treating patients until the end of the full-trial recruitment period (Figure 3).
Potential cases
Screening
Identified in
IAPT clinics
GAD-7 score > 10 
(n = 11,880)
Stepped up
from low-level 
IAPT (20%)
(n = 2376)
Not stepped
up (80%)
(n = 9504)
Do not wish to
be considered
(67%)
(n = 1584)
Consent to be 
considered for the 
trial and screened 
using the MINI (33%)
(n = 792)
GAD and major 
depression, and 
excluded (50%)
(n = 396)
GAD main 
diagnosis 
(50%)
(n = 396)
Satisfy entry 
and consent
Satisfy all 
entry criteria and
consent (90%)
(n = 360)
Do not satisfy all
entry criteria
and excluded 
(10%)
(n = 36)
Assumptions made: (1) 67% of those with a GAD-7 score ≥ 10 and suitable to be stepped up will 
be on antidepressants already or decline to be randomised; and (2) 50% of those agreeing to 
be considered for the trial will be excluded because they have current major depression. 
FIGURE 2 Planned screening and recruitment across the 2 years of ToSCA. GAD trial recruitment includes
pilot phase.
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In the event, we had four pilot IAPT sites in London, Central and South West England that agreed to take
part at this stage and would have provided a range of populations; the London boroughs of Camden and
Islington together with Kingston (all managed by the same IAPT service), Greenwich, Bristol, and Coventry
and Warwickshire. Because of their relatively larger populations and IAPT service throughput, Camden
and Islington with Kingston and Coventry and Warwickshire had target recruitment rates during the period
of the internal pilot that were double those of Greenwich and Bristol.
TABLE 2 Planned recruitment rates from the four pilot sites for the first year of the trial
ToSCA IAPT pilot sites Pilot recruitment target, n
Camden and Islington with Kingston 24–36
Coventry and Warwickshire 24–36
Bristol 12–18
Greenwich 12–18
Total 72–108
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Responses written and sent to HTA queries
Contract reviewed and agreed with UCL
Subcontract to be agreed with Imperial College London
Protocol review and work-up with UCL JRO (Research
sponsor) – to include resolution of IMP (sertraline)
issues and site feasibility
Agreed start date of 1 August 2014 
Recruitment of trial staff (can start before funding
awarded, but need funding in place for staff contracts 
to be signed)
MHRA/REC submission package preparation (commence 
before start date if JRO queries sorted) 
Potential wait for REC committee availability
MHRA/REC review period
Local NHS permission review
Sponsor initiation procedures
Writing of study manuals including SOPs (need staff 
in post to do this)
Initial liaison with pilot sites
Pilot site therapist training
Testing of recruitment methods at pilot sites
Pilot trial recruitment
Pilot trial treatment and follow-upa
Pilot collection of outcome measures
Recruit and train main trial sitesb
Main trial recruitment
Main trial treatment and follow-up
Analysis and writing up
TSC and DMEC meetings ™ ™ D ™ ™ D
Assess if pilot trial successful – end January 2016
20152014 2016 2017
FIGURE 3 Proposed timelines for ToSCA, with a start date of 1 August 2014. a, We will offer treatment to completion
to all participants recruited to the internal pilot even if not proceeding to the full trial; b, Start training therapist at
the other sites in preparation for the full trial. D, Data Monitoring and Ethics Committee meeting; DMEC, Data
Monitoring and Ethics Committee; IMP, investigational medicinal product; SOP, standard operating procedure;
TSC, Trial Steering Committee.
DOI: 10.3310/hta21450 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 45
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Buszewicz et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
The IAPT sites agreed to provide high-intensity CBT for 50% of the participants recruited. The number of
therapists and supervisors trained was proportional to their target.
Because of the delays described in the previous chapter with obtaining research governance approvals as
well as the sponsorship and site initiation processes (see Chapter 3), the first pilot site to open to recruitment
was Camden and Islington with Kingston on 1 July 2015 (see Site initiation visits, opening to recruitment
and standard operating procedures below), which was 5 months later than originally planned and meant
that our 12-month internal pilot phase would have been due to end on 30 June 2016.
Trial preparation: staff training
Training of high-intensity cognitive behavioural therapists
A 2-day training session in London on 22 and 23 January 2015 was arranged for the IAPT high-intensity
CBT therapists and their supervisors from each of the pilot sites, and was delivered by Professor Michel
Dugas who came over from Canada to deliver the training (see Appendix 9 and Chapter 6).
Liaison with and training of low-intensity psychological well-being practitioners
In preparation for each pilot site opening for recruitment, training sessions were held with the IAPT
psychological well-being practitioners (PWPs) at each site. Their purpose was to prepare the PWPs for
their part in identifying suitable participants for the study (see Appendix 10).
Training of research staff to conduct informed consent, eligibility assessment and
baseline measures
Two half-day training sessions were conducted for any member of the research staff who might be
involved in the baseline recruitment process – this included a combination of the research staff based at
the UCL central trial office and lead PWPs or clinical studies officers involved in these procedures at the
pilot sites. The first session was held on 5 May 2015 in London and included the trial co-ordinator,
Dr Anastasia Kalpakidou, the Bristol Clinical Studies Officer, Joy Farrimond, and lead PWPs from
Camden, Islington and Kingston (Tarun Limbachaya, Annie Ormond, Elliott Rose, Rachel Lawrence and
Natalie Gunn).
The second training session was held on 16 July 2015 in Nuneaton near Coventry and included the trial
co-ordinator, Dr Anastasia Kalpakidou, research assistant Sally Gascoine, ToSCA intern Alessandro Bosco
and the Coventry and Warwickshire lead PWP and clinical studies officers (Helen Fletcher, James Tucker,
Abayomi Shomoyei and Emily Benson).
Current good clinical practice accreditation was a condition of having a research staff role on the trial
(see Appendix 11).
The central research team produced a full training/recruitment manual for participating sites with all the
relevant questionnaires and outcome measures as appendices for reference. This was distributed in draft
version to participants at the training sessions and the full electronic version sent to the pilot sites when
they were open to recruitment (manual available on request).
General practitioner recruitment processes
As recruitment of patients to the trial was via the IAPT PWPs, the GPs who would potentially be taking
part in the study were identified only once their patient(s) had expressed an interest in being assessed for
the trial. At this point they were contacted with their patient’s consent and asked to complete a Medical
Suitability Review form to check that there were no known medical contraindications to them being
prescribed sertraline, should they be randomised to that intervention arm in the trial (see Appendix 2).
CONDUCT OF THE TRIAL
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In order to forewarn the local GPs and hopefully gain their co-operation with the study and a speedy
response to any request for completion of the Medical Suitability Review form once requested, all the GPs
in the areas where the pilot IAPT sites were situated were informed about the study in advance via their
local primary care leads within their CRN structure. The procedures for this varied slightly between areas
according to the procedures that they normally followed, but consisted, in essence, of an e-mail notifying
the practices about ToSCA with an attached flyer (see Appendix 12) that informed them about the three
potential procedures that they might be asked to assist with if one of their patients was recruited to the
study, and the relevant rates of reimbursement per patient:
l completion of the GP Medication Suitability Review – reimbursed at £35
l prescribing sertraline for a period of 12 months or as appropriate – reimbursed at £140 in accordance
with clinical guidelines (only applied to patients in the sertraline arm of the trial)
l facilitating collection of health services data at the end of the trial – reimbursed at £20.
The primary care leads of the two London CRNs involved (North Thames and South London) asked their
local GPs to respond to this initial notification by sending an expression of interest in taking part in the
trial, which would be the normal process for recruiting interested general practices. Very few practices
responded in this way in either area, but this was not a major issue as the chances of patients being
recruited to the trial from any individual practice were small.
ToSCA video
The North Central London Research Consortium, which supports primary care and mental health research
in north central London where the central research site at UCL is located, also funded the production of a
promotional video about ToSCA for GPs to watch. This included some educational material about GAD as
well as a brief description of the background to the trial and details of the reimbursement rates for GP
practices with patients involved in the trial. It was the first time this methodology had been tried.
General practices in the local area (i.e. Camden and Islington with Kingston) were reimbursed £70 if they
arranged to view this video within a practice clinical meeting and could give evidence of the GPs in the
practice having watched it. Ten practices were reimbursed for watching the video: seven in Camden
(out of a total of 40 practices) and three in Islington (out of a total of 38 practices). Of these, all but one
practice in Islington expressed an interest in taking part in the study if any of their patients were
potentially eligible.
Interest was also expressed in the video by the other pilot sites where the North Central London Research
Consortium was not in a position to reimburse the practices, and they were given the link to the video to
watch if they wished. This has now entered the public arena via YouTube (YouTube, LLC, San Bruno,
CA, USA).55
Site initiation visits, opening to recruitment and standard operating
procedures
As described in Chapter 3, significant delays in obtaining research governance approval for the study as
well as delays in some of the sponsorship processes meant that we were able only to start recruiting
participants to the trial 5 months later than anticipated (i.e. at the beginning of July 2015 rather than
1 February 2015 as initially planned).
The central co-ordinating site based at the UCL Research Department of Primary Care and Population
Health had its site initiation visit conducted by the UCL JRO on 29 May 2015 and the trial was declared
open to recruitment from 1 July 2015.
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The first pilot site initiation visit was at Camden and Islington with Kingston on 5 June 2015, and the site
was also declared open to recruitment from 1 July 2015.
The Greenwich site initiation visit took place on 28 July 2015 and the site was declared open to recruitment
on 17 August 2015.
The Coventry and Warwickshire site initiation visit took place on 29 June 2015 and the site was declared
open to recruitment on 3 September 2015 (the delay between site initiation and opening to recruitment
was because of discussions regarding whether or not the PI at this site might change; this was then
decided against and an updating teleconference to ensure that the site was up to date with all the
required procedures was held on 3 September 2015).
The Bristol site initiation visit took place on 27 August 2015 and the site was declared open to recruitment
on 8 September 2015.
The research team worked with the PRIMENT CTU and the UCL JRO to identify the relevant standard
operating procedures for the trial, and ensured that all relevant staff, centrally and at the pilot sites, were
trained in their use and had signed the relevant registers confirming this.
CONDUCT OF THE TRIAL
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Chapter 5 Participant recruitment: actual
recruitment rates versus planned recruitment rate and
strategies used to try and improve this
Participant recruitment to the trial
Once the sites were open to recruitment, both the screening and recruitment of trial participants was very
slow. The results of screening and recruitment are summarised in Figure 4, the CONSORT diagram
covering the time period from 1 July 2015 until 18 February 2016 following a monitoring meeting with the
NIHR HTA programme, which took place on 14 January 2016 (see Table 3 for further details).
Details of recruitment are described in Table 3. The first participant recruited to the trial was from Camden
and Islington with Kingston, and was assessed on 29 September 2015 and randomised on 1 October 2015.
The second participant was from Greenwich, assessed on 18 November 2015 and randomised on
20 November 2015. The next three participants recruited came from Camden and Islington with Kingston
(one participant), and Coventry and Warwickshire (two participants), and were randomised on 19 November
2015 and 4 and 6 January 2016. All were assessed no more than 2 working days previously – the participant
randomised on 4 January 2016 had been assessed on 30 December 2015 just prior to the New Year holiday.
Screened
(n = 60)
Assessed for eligibility (baseline)
(n = 7)
Randomised
(n = 5)
Excluded
(n = 53)
• Ineligible, n = 2
• Declined to participate, n = 45
• GP declined patient’s 
   participation, n = 2
• Baselines cancelled as a result 
   of study closure, n = 4
Enrolment
Excluded
(n = 2)
• Ineligible, n = 2
Allocated to treatment A
(n = 3)
• Received treatment A, n = 2
• Not contactable, presumed 
   withdrawn, n = 1
Allocated to treatment B
(n = 2)
• Received treatment B, n = 2Allocation
FIGURE 4 The CONSORT diagram showing participant recruitment and allocation.
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In addition, two potential participants were found ineligible for the trial at the baseline assessment –
one from Coventry and Warwickshire assessed on 29 October 2015, who was uncertain whether or
not GAD was the most important issue affecting their mental health, and one from Bristol assessed on
7 January 2016, who was excluded because they had current major depression as assessed on the
MINI questionnaire.43
In a further two cases (both in Camden and Islington with Kingston), their GPs were not prepared to agree
to have their patients in the trial or to prescribe sertraline for their GAD should they be randomised to
the medication arm, so it was not possible to proceed with the baseline assessment despite the patients
expressing an interest in taking part in the trial.
A little ironically, a further four potential participants identified in January 2016 (two from Coventry and
Warwickshire and two from Bristol) had to have their baseline assessments cancelled following the NIHR
HTA programme decision to withdraw funding from the trial (see Chapter 8).
Actual recruitment rates versus planned recruitment rate
We had anticipated that recruitment would be slow in the first 3 months of the internal pilot while we
were testing our recruitment methods, but had expected it to improve after this as the pilot sites became
familiar with participant identification and recruitment processes. In our submitted key progress figures we
indicated that we expected to recruit two participants in the first month, three in the second, four in the
third, five in the fourth and then 10 participants in each of the following 8 months – resulting in an
anticipated total recruitment of 90 participants over the 12-month period of the internal pilot. We had an
internal pilot target to achieve at least 70% of this (i.e. 63 participants recruited at 1 year).
The very slow rate of recruitment to the trial unfortunately meant that at the end of January 2016,
7 months into the internal pilot, we had recruited only seven participants, as opposed to the projected
40 anticipated (Figure 5). This was despite trying a variety of strategies to improve the recruitment rates,
as described in following sections.
Reasons for difficulties with recruitment
The most noticeable factor was that we had fewer potential participants identified by the PWPs than we
had anticipated from our earlier data, and of the 60 potential participants identified at screening, 45
declined to participate – the majority (n = 30) because of their reluctance to be randomised to medication,
with a further person not wishing to take medication for > 6 months. Four people only wanted CBT, one
wanted a combination of antidepressants and CBT, and one went to their GP to obtain this. One person
was already on medication (SSRIs), one had found it hard to engage with CBT, two did not think that
their GAD was their main clinical priority, two did not want to take part in research, one did not give any
reason for not taking part and one travelled extensively and, hence, could not keep regular clinical
appointments as would have been expected with participation in the trial (see Chapter 8).
The research team worked hard to try and address all the possible factors contributing to this lower than
anticipated identification rate, detailed in the next section.
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Methods aiming to improve recruitment via psychological well-being
practitioners
As soon as the research team became aware of the difficulties with participant recruitment, a number of
methods were used to attempt to improve recruitment of participants by PWPs. These included:
l materials to help the PWPs keep in mind the study and recruitment
l funding of lead PWPs to facilitate recruitment
l reminders to PWPs about the study
l meetings with PWPs about the study
l database searches to identify possible cases.
Various materials were distributed to PWPs to serve as reminders of the study and recruitment processes.
A flow chart on a single sheet set out the recruitment criteria, key points to discuss with possible eligible
participants, what to do if participants agreed to be contacted by the research team or were unsure, and the
logging of the outcome of these discussions. Copies of this were posted at PWPs’ work stations (Figure 6)
and in the materials PWPs took with them to clinics.
In addition, each site had one or more PWPs who were part-funded from local R&D funds to help
with recruitment and baseline assessments. These PWPs were embedded in their local IAPT services as
they worked clinically as PWPs in their service as well as having dedicated funded sessions to facilitate
recruitment. On a day-to-day basis they liaised with their PWP colleagues, reminding them of the study
both individually and in team meetings, and giving advice regarding recruitment. Several sites used the
PWP case management supervision sessions to consider suggesting assessment for the trial to patients
likely to have GAD at their 4-week review.
To monitor recruitment, the lead PWPs completed log sheets of potentially eligible participants and the
outcome of the PWP discussions with potential participants about the study. These were to be returned
fortnightly to the research team. The routine of requesting these to be returned each fortnight and
prompting if log sheets had not been returned served as a repeated reminder about the study and also
gave them the opportunity to enquire about any issues regarding recruitment.
In some sites, the local PI and/or members of the study research team attended routine PWP team
meetings to remind them about the study and problem-solve issues regarding recruitment. As the study
progressed, and it became evident that there were greater than anticipated barriers to recruitment, the
ToSCA (Trial of HI CBT vs. Sertraline)
When should I think about the trial?
• Towards the end of treatment/before stepping up/before discharge
What to look for?
• Patients who have not recovered following course of LI treatment 
   (e.g. GSH, groups, workshop, BOP, cCBT)
• GAD-7 > 10
• Possible diagnosis of GAD
• Not currently taking antidepressant medication 
What to do next?
• Discuss trial with patient – see ToSCA pack and flow chart 
   (Contact xxxxxx with the outcome of your discussion)
FIGURE 6 Example of reminder for PWPs attached to their monitors in Camden and Islington. BOP, books on
prescription; cCBT, computerised cognitive behavioural therapy; GSH, guided self-help; HI, high intensity;
LI, low intensity.
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focus of these discussions was on identifying barriers that the PWPs might have in raising the study with
potentially eligible participants or in pursuing these discussions in a sufficiently facilitative manner.
There were some common themes that emerged that may have contributed to the relatively low levels of
identification of potential participants by the PWPs and that may be worth considering when planning
future studies involving IAPT services.
Reasons given by psychological well-being practitioners for the difficulty recruiting
participants to ToSCA
l We explained to the PWPs in both the written materials and face-to-face training the importance of
having equipoise in explaining the trial to potential participants, and that it was an important
unanswered clinical question whether CBT or medication would be the most effective treatment for
these patients. However, the fact that they had been trained to deliver a low-intensity CBT intervention
is likely to have given them both an overt and also less conscious bias towards psychological therapy
treatments.
l A number of PWPs said that they thought many patients they saw were against trying psychotropic
medication. This was backed up by many of the documented patient responses to being told about the
trial, but it was unclear if the patients may have been influenced in this by the PWPs. We gave the
PWPs examples of answers to give to patients who might have been concerned about the side effects
of medication (Box 2).
l Several PWPs were concerned that patients would not be offered CBT after trying medication if the
medication proved unhelpful, possibly indicating a greater enthusiasm for psychological therapy.
l Some PWPs said they thought GAD was not as prevalent in the clinical population as generally believed
and that, in their experience, GAD presentations are often not the focus of psychological treatment.
l Quite a few PWPs wanted to be certain that people they discussed the trial with had GAD, although
we had stated that this was not possible at their stage in the process and that we would like them to
offer the possibility of the trial to anyone with a reasonable likelihood of GAD, as they would then
need to be assessed using the gold standard MINI questionnaire. The PWPs said they were concerned
about wasting clients’ time if they did not have GAD.
l Time pressures were a virtually universal problem – all the PWPs had significant clinical caseloads and
found it difficult to keep the trial in mind.
l Many PWPs reported that their clients were very anxious about the uncertainty of being referred and
allocated to a random treatment. Given that their key problem is likely to have been GAD, with a core
component being worry about uncertainty, this illustrates the potential difficulty of recruiting
participants to a RCT in GAD. When this barrier was identified, PWPs were encouraged to suggest to
potential participants that they meet with the researcher and address their questions to the researcher,
rather than the PWP attempting to answer them.
l This problem with worry about uncertainty also made the PWPs concerned about making their patients
more anxious when discussing the trial, with implications for their workload, as well as concern for the
well-being of their patients.
A further unanticipated barrier identified through these discussions was that the supervisors of the PWPs
often considered that a comorbid problem which the patient had, either diagnostic (e.g. social anxiety) or
psychosocial (e.g. debt problems or relationship difficulties), was the key clinical issue to address and
would direct the PWP to refer the patient for an intervention addressing this problem which meant they
were not considered for the study. When this barrier was identified, local PIs and the study team
encouraged PWPs and supervisors to refer such patients for a ToSCA baseline assessment where the
suitability of treatment for GAD would be addressed rather than pre-empting this.
DOI: 10.3310/hta21450 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 45
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Buszewicz et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
IAPTUS database searches
Two months into recruitment at the first site in Camden and Islington with Kingston, there was a pilot of
using the routine service clinical database (IAPTUS; adult version, Mayden, Bath) to identify potential cases.
Two types of case identification method were piloted: a retrospective and prospective method.
For both methods it was staff at the pilot site (the lead PWPs) who conducted the searches.
Retrospective database searches
The retrospective method was initially used to identify cases potentially meeting study criteria, who had
been discharged from low-intensity PWP treatment and stepped up to be awaiting high-intensity CBT
within the service. It did not prove to be very useful in terms of identifying potential participants for the
trial as, of the 18 patients who had been referred for stepping up who still had a GAD score of ≥ 10, nine
had depression as their main problem, two had other clinical problems they wanted to address, one had
moved, one dropped out, two declined as they did not want medication and three did not respond. There
were also 14 patients who had been discharged from the IAPT service despite still having a GAD score of
≥ 10, of whom six reported having other clinical presentations as their main problem, one declined when
contacted about the study and seven did not respond.
Following on from this, we examined the participant flow for the whole trial recruitment period
retrospectively and this indicated a significant number of people who might have been suitable to
approach to discuss assessment for participation in the trial who had not been identified by the PWPs.
Using the IAPTUS database, the flow of people with GAD-7 scores of ≥ 10 during the active study
recruitment period was analysed at the IAPT pilot site covering the same two local London boroughs used
to estimate likely recruitment flows in 2011–12 before the trial (i.e. Camden and Islington with Kingston).
Approximately 1 in 4 people assessed for treatment with a GAD-7 score of ≥ 10 were seen for at least
three sessions of a low-intensity treatment (the other three out of four people either went straight to
high-intensity CBT or were discharged, referred on or dropped out before having two low-intensity treatment
sessions). Of those who completed at least three sessions of a low-intensity intervention, 37% were being a
prescribed a psychotropic medication (data missing on a further 2%), and 50% of those who were not
prescribed medication improved and had GAD-7 scores of < 10 at the end of their low-intensity treatment.
All of these therefore did not meet criteria for inclusion in the study.
BOX 2 Suggested PWP script if patient is concerned about being randomised to medication
If the potential participant is not keen to take part in the trial because of concerns about being randomised/
allocated to the medication arm, it’s suggested that you ask them if they could say what it is about the
medication that concerns them and see if this can be briefly discussed. The following are some common
preconceptions about antidepressant medication such as the SSRI sertraline.
(a) That they will be addictive: there is no evidence of any physical addiction with a medication like sertraline,
although it is better to stop it gradually rather than suddenly.
(b) That they will make people feel like ‘zombies’ and not themselves: again, there is no evidence of this.
People do sometimes experience mild side effects when starting sertraline, such as nausea, dizziness and
tiredness, but these are usually mild and short lasting, and sertraline has been prescribed in millions of
doses worldwide with a very good safety profile.
(c) Sertraline has been shown in trials to be effective for GAD; what we do not know is whether it’s more or
less effective than the psychological CBT treatment also being offered.
You could then see if the patient feels their concerns have been addressed and they are happy to consider
being in the trial, if eligible, or if they still feel clear that they do not want to do this.
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Of those patients who were not on medication and had not recovered, a proportion dropped out of
treatment before the end of their low-intensity intervention and would not have been able to be
approached by their low-intensity worker about the study. However, of those who remained potentially
approachable to discuss the trial, approximately only 1 in 6 had been identified to the study team as
having been approached about the study by their low-intensity worker/PWP. Unfortunately, following a
change in the clinical database used by the IAPT service, the completion of diagnostic coding during the
recruitment period was poor (only 28% of people with GAD-7 scores of ≥ 10 had primary diagnoses
coded on the system) and so we were unable to use this to calculate how many of the potentially eligible
and approachable patients were considered by their IAPT low-intensity worker to have a primary diagnosis
of GAD rather than other diagnoses.
Prospective database searches
The prospective identification method was used to identify cases potentially meeting the study criteria who
had already had three or more sessions of PWP treatment and were still in treatment with a PWP. It was
instituted on a regular basis at the Camden and Islington with Kingston site, and the algorithms and
methods were disseminated to the other pilot sites. On a regular fortnightly basis, cases were extracted
from the IAPTUS database that met the following criteria:
1. most recent GAD-7 score of ≥ 10
2. seen three or more times in a step 2 treatment (could include the PWP assessment session)
3. still in a step 2 treatment
4. not on a psychotropic medication.
An e-mail was sent to the PWP treating each patient identified through these searches, giving the patient’s
identification details, noting that the patient was potentially eligible for ToSCA and asking the PWP to
e-mail, by return, if there was some reason that they were not eligible for the study (e.g. that the patient
had an agreed diagnosis or diagnoses other than GAD).
In addition, a note was placed on the front page of the patient’s electronic records in IAPTUS (on the page
that first comes up when the patient’s records are entered) that the patient was potentially eligible
for ToSCA.
Using the standard IAPTUS search to identify people at step 2 who had a diagnosis of GAD highlighted a
problem that people had not always been given an accurate provisional diagnosis. In order to identify
potentially eligible participants, this involved checking clinical records for GAD scores, session number and
medication use.
General practitioner factors affecting participant recruitment
As the trial participants were being recruited via the IAPT service and not their GPs, we were relying on
their GPs agreeing to support the trial in terms of checking their patient’s medical suitability for the trial
and agreeing to prescribe sertraline for those randomised to the medication arm once the patients had
expressed an interest in taking part. We sent information to all the local GPs about the potential benefits
of the trial for their patients, and the trial procedures and rates of reimbursement that would affect them
via the local primary care research networks before the trial opened (see Chapter 2, Methods).
Thirteen GPs were approached with patient consent to complete Medication Suitability Review forms
(i.e. for the five randomised participants, the two participants found to be ineligible at the baseline
assessment and four participants whose baseline assessments were cancelled because the trial was
terminated). Two GPs refused to complete the form for their patients.
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Eleven GPs therefore completed the form and returned it. Of the two GPs who were not happy to do so,
one considered that their patient had current physical problems that would make it inappropriate for them
to take part in the trial despite the patient wanting to participate and the other GP simply refused to have
any involvement. The research team attempted to contact both GPs to discuss the issues with them but
without success.
Given the design of the study we did not consider there were any other strategies that might have allowed
these two patients to participate, although they were disappointed to be excluded.
Feedback from study participants
As the trial was terminated prematurely we had only collected data at the 3-month time point from one
participant and did not have a meaningful number of data to analyse. The five participants who had been
recruited to the trial were all sent written notification that the study was finishing early but that we had
made arrangements with their GPs or IAPT therapists to continue providing them with the intervention to
which they had been randomised. The research team also contacted the participants in person to check
that they had understood the implications of the trial finishing early and to get their feedback about
participating in the trial in lieu of any formal results.
Out of the five randomised participants, four were spoken to via either telephone or e-mail.
1. Sertraline 1 (by telephone): was glad to have taken part. Had a positive response in terms of mood,
but switched to citalopram the week of being contacted as a result of side effects.
2. Sertraline 2 (by e-mail): reported that everything is going well with the treatment.
3. Sertraline 3 (unable to contact): participant was presumed to have withdrawn/dropped out.
4. CBT 1 (by e-mail): travelling so unaware of trial closure. Was sorry that the trial was closing – reported
that it had been a ‘really positive experience’ and offered to provide more specific feedback if necessary.
5. CBT 2 (by telephone): treatment ongoing. Felt very disappointed when the trial closed, which had a
negative effect on mood. Still very anxious in general and unsure when the CBT treatment will end.
Appreciated the follow-up call as they wanted to be able to give their views about the study closure.
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Chapter 6 Cognitive behavioural therapy
subgroup, cognitive behavioural therapy measures of
competence and adherence, training and supervision
of high-intensity therapists, and validation of tapes
Cognitive behavioural therapy subgroup
A CBT subgroup comprising Michel Dugas, Roz Shafran, Marc Serfaty, John Cape and Marta Buszewicz
met by teleconference every 2 months during the study to discuss and confirm the procedures regarding
delivery of the CBT intervention, as well as the processes for the assessment of therapist competence and
adherence. This was also an opportunity for the group to discuss any issues that had come up in the
expert supervision of the pilot site supervisors by Michel Dugas and Roz Shafran, and to keep the group
informed about any general trial issues of relevance.
Background to cognitive behavioural therapy measures of competence
and adherence
Lichstein et al.56 described three important elements when evaluating CBT: first, whether or not a
treatment was delivered by the therapist in accordance with the intervention model; second, whether or
not there was ‘receipt’ by the patient (i.e. had it been understood); and, third, whether or not enactment
had occurred (i.e. had the patient carried out the prescribed treatment). The parallel elements in the drug
arm of ToSCA would be whether or not sertraline had been properly prescribed, whether or not the
patient had understood how to take the medication (collected the prescription, understood the timing,
dose, etc.) and whether or not they had actually taken the medication.
There are two main issues that were considered when deciding how to rate the CBT therapy delivered in
this trial: first, did the therapist adhere to the Dugas Therapists’ Manual (see Appendix 13) by delivering
interventions specified for the treatment of GAD (adherence); and, second, was the approach to delivering
the therapy of a sufficiently high standard to be considered competently delivered (competence)?
Assessment of adherence and competence is required to make sure that the trial is testing the intervention as
it was designed to be delivered. In effectiveness studies, such as the current one, it can be more difficult to
ensure adherence and competence because of the challenges inherent in delivering the treatment in routine
clinical services. To maximise adherence and competence to the protocol, therapists must be trained and
closely supervised. Within IAPT services all qualified therapists are accredited by the professional organisation,
the British Association of Behavioural and Cognitive Psychotherapy. This accreditation is not in itself sufficient
assurance that the specific protocol for the treatment of GAD selected for this trial will be delivered with high
levels of adherence and competence. Some of the therapists and supervisors may not have been trained to
deliver the Dugas model37 but others might, and ensuring that all the therapists were able to deliver the
protocol competently, and that the supervisors were able to supervise the delivery of the protocol within the
clinical service, were key components of the study. The Dugas model was selected as the CBT protocol of
choice because of the data supporting its efficacy as well as availability of training materials.57
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Assessment of competence
A scale for measuring therapist competence in cognitive therapy, based on the original Cognitive Therapy
Scale,58 is the 12-item Cognitive Therapy Scale-Revised (CTS-R).59 This revised version improves on the
original Cognitive Therapy Scale by eliminating the overlap between items, improves on the scaling system
and defines items more clearly. In this trial we planned to have an independent rater listening to audio-
recordings of therapy sessions using the CTS-R.
Scoring
The CTS-R consists of 12 items: agenda-setting and adherence; feedback; collaboration; pacing and
efficient use of time; interpersonal effectiveness; eliciting of appropriate emotional expression; eliciting key
cognitions; eliciting and planning behaviours; guided discovery; conceptual integration; application of
change methods; and homework setting. The CTS-R is more specific than the original Cognitive Therapy
Scale in that therapist competence is defined very precisely. Each item is rated from 0 to 6 on a visual
analogue scale ranging from incompetent, through to novice, advanced beginner, competent, proficient
and expert. The total score ranges between 0 and 72, with a minimum score of 36 taken as competency
for the delivery of therapy.
Assessment of adherence
In this context we defined therapist adherence as the extent to which the therapist stuck to the essential
elements described within the treatment manual.
We aimed to collect detailed information about the content of the intervention using a Therapy
Components Checklist (TCC), which was developed for use in the trial. The TCC summarises five main
interventions described in the Dugas treatment manual (see Appendix 13) and deemed essential for
successful treatment. Each of these areas is made up of a number of elements:
1. psychoeducation and worry work (three elements)
2. evaluation of the usefulness of worry (two elements)
3. uncertainty recognition/exposure (three elements)
4. problem-solving (three elements)
5. written exposure (five elements).
The TCC also includes sections about general therapy procedures (10 elements) and the specific materials
used (nine elements). We also aimed to collect information about a number of interventions that are not
permitted and, if used, to assess deviations from the protocol (e.g. use of controlled worry periods). There is
one TCC completed per patient and the therapist reports which components were addressed after each
therapy session. A more detailed description of these can be seen by referring to the TCC (see Appendix 14).
The TCC was used in supervision, but not shared with the patient.
At the very end of a course of therapy, up to 16 sessions, the main elements of the treatment delivered
are summarised in the brief End of Therapy Checklist (EoTC) (see Appendix 15) completed by the therapist.
This consists of the same five main areas/interventions detailed above. The EoTC was not used in
supervision or therapy, but solely for the purpose of assessing adherence. This was also developed by the
CBT group for use in the trial.
Defining ‘sufficient’ adherence
The degree of adherence was rated using the EoTC as follows:
l 0 – non-adherent (between zero and two out of the five components delivered on the EoTC, i.e.
< 40% of the session was spent using methods from the protocol; the rest of the time was spent on
methods not in the protocol or generic techniques, such as empathic listening)
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l 1 – somewhat adherent (two or three out of the five components delivered on the EoTC, i.e. 40–59%
of the session was spent using methods from the protocol; the rest of the time was spent on methods
not in the protocol or generic techniques)
l 2 – mostly adherent (three or four out of the five components delivered on the EoTC, i.e. 60–79% of
the session was spent using methods from the protocol; the rest of the time was spent on methods not
in the protocol or generic techniques)
l 3 – fully adherent (at least four out of the five components delivered on by the EoTC, i.e. ≥ 80% of the
session was spent using methods from the protocol; the rest of the time was spent on methods not in
the protocol or generic techniques).
Data collection
Therapists’ ratings of adherence
The therapists would have been asked to complete (1) the TCC at the end of every therapy session as well
as (2) summarising the treatment delivered during a course of therapy using the EoTC.
Independent ratings of adherence
An independent rater would have been asked to listen to all of the audio-recordings available on a patient
who had completed therapy and objectively rate adherence using the EoTC, giving a score generated by
adding all of the items rated as adhered to on a scale. A representative sample through random selection
of 10% of all the patients can be selected and an EoTC completed for each patient. An average score can
then be generated to see if the study complied with the goal of ensuring that treatment delivery was at
least mostly adherent to the protocol using the method set out above.
Training and supervision arrangements for ToSCA
Training workshop
Training for ToSCA consisted of a 2-day workshop, on 22 and 23 January 2015, led by Professor Michel
Dugas, who developed the CBT intervention being used in this trial and has conducted previous trials
in GAD.
Attendees included the CI (MB), co-applicants from the project who are experienced CBT therapists
(RS, MS and JC) and staff from the IAPT pilot centres located in south-east England – London (Camden,
Islington, Greenwich), Surrey (Kingston), the Midlands (Coventry, Warwickshire) and the west of England
(Bristol). The IAPT staff at each of these sites were very enthusiastic about the opportunity to receive
training from Michel Dugas and places had to be limited to two therapists and one supervisor for each
single pilot site (i.e. Greenwich and Bristol) and four therapists and two supervisors for the sites committed
to a double recruitment figure (i.e. Camden and Islington with Kingston, and Coventry and Warwickshire)
(see Appendix 9).
The training was delivered as a workshop, with scenarios in which attendees were encouraged to get into
groups and practise using role play. It was based on the manual provided by Michel Dugas, and each
therapist and supervisor was given a copy for use in the trial (see Appendix 13).
Plan to ensure therapist competence
All attendees met at the end of training on the final day to discuss implementation issues at their local
sites. The plan was for each therapist who was going to be involved in ToSCA to treat two patients who
had already been identified as having GAD within the IAPT service, using the manualised intervention that
they had been trained in using by Michel Dugas. These patients would be used to help therapists and
supervisors become familiar with the protocol, and optimise adherence and competence for the main trial.
As these patients had not been recruited or consented to take part in the trial, it was not possible for the
tapes or transcripts of their therapy sessions to be made available to the external supervisors. The local
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supervisors brought any particular issues arising from the treatment of these patients to their ‘supervision
of supervision’ sessions provided by Michel Dugas and Roz Shafran. We have termed the patients treated
in this way ‘practice patients’, in order to distinguish them from patients who were recruited for the
internal pilot who underwent a rigorous eligibility and consent process.
It was agreed that in the practice patient stage the therapists would need to treat at least two patients and
the supervisors would rate the therapist on at least one session using the CTS-R.60 It was agreed that the
therapists would need to have achieved a score of ≥ 36 to be considered competent and be permitted to
treat patients in the trial. A minimum score of 36 is the standard criterion for competence within IAPT
services. It was intended that competence in the delivery of CBT for the main trial would be assessed in the
same way (i.e. a score of ≥ 36 according to the CTS-R). In the main trial, it was intended that an expert
rater (Melissa Robichaud) would independently rate 10% of all therapy sessions using the CTS-R to
establish that the protocol had been delivered competently. In the unlikely event that the therapy had not
been delivered with competence or adherence to the protocol, this would have been reported.
Plan to ensure therapist adherence
Adherence to the protocol is a critical part of any trial. We therefore developed a measure of adherence to
the protocol for use in the main trial. The practice patient stage enabled us to test the feasibility of this
measure. As described in Assessment of adherence, the TCC is intended to be completed after every
session by the therapist to record the main content of the session, and the EoTC is designed to be
completed at the end of the course of therapy by the therapist. The therapists were asked to bring the
TCC completed on their ‘practice patients’ to their supervision sessions so that the local supervisors could
help them maintain adherence to the protocol.
We planned to also use the TCC in the main trial to assess adherence, in addition to external assessment
of adherence to the protocol by an expert rater (Melissa Robichaud), who had agreed to rate 10% of the
sessions selected at random to ensure that the therapists had adhered to the protocol. The intention was
for the external rater to listen to 10% of the sessions selected at random and rate them for adherence and
competence simultaneously. We planned to examine the relationship between therapist self-ratings of
adherence and external expert ratings of adherence. If there was a strong and positive relationship
between the ratings, we could conclude that therapist ratings of adherence were accurate reflections of
the content of therapy, which would allow future research to dispense with the need for costly
independent ratings.
Supervision structures
The IAPT therapists were supervised by local IAPT leads from the participating centres – both the supervisors
and therapists were all British Association of Behavioural and Cognitive Psychotherapy-accredited therapists.
The IAPT supervisors from Kingston, Camden and Islington and Bristol were externally supervised by
Roz Shafran and those from Greenwich, Coventry and Warwickshire by Michel Dugas. Both external
supervisors were ToSCA co-applicants.
Routine supervision of therapy in IAPT takes place at least monthly, but is flexible within this period.
However, in this trial, we recommended flexibility so that if any immediate issues needed attention, the
therapists could consult their IAPT supervisors. The external ToSCA supervisors (RS and MD) provided
additional monthly supervision sessions (‘supervision of supervision’) by teleconference link to the IAPT
supervisors, which was part of the trial process and was in addition to usual clinical practice. The external
ToSCA supervisors were also accessible to the local IAPT supervisors by e-mail to answer any additional
queries that arose between supervision sessions.
Flexibility in the practice patient stage was used to learn about how clarification and modifications to the
CBT intervention might be required. This was done by keeping rigorous notes during supervision to help
inform the project, as well as e-mail discussions between the supervisors and the trial team. It was agreed
that once the ‘practice phase’ had finished, there would be no modifications to the protocol allowed.
COGNITIVE BEHAVIOURAL THERAPY SUBGROUP
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
Findings and recommendations following the practice patient stage
Supervision
Direct supervision of IAPT therapists in the services took place, on average, monthly for between 60 and
90 minutes individually, in pairs or in groups of three or four, depending on the service. The expert
‘supervision of supervision’ (i.e. supervision of the IAPT supervisors by RS and MD) also took place monthly
between July 2015 and January 2016 for 60 minutes. This was done over a dial-in telephone service, with
times and dates agreed in advance. Michel Dugas supervised four IAPT supervisors directly and Roz Shafran
supervised three. A total of 12 supervision sessions took place, six for each of the supervisors, monthly,
with the exception of August 2015. Detailed notes were kept with any queries about protocols minuted
and addressed at the next supervision session after consultation with the research team.
Patients treated with cognitive behavioural therapy
Of the team supervised by Roz Shafran, 7 out of the 11 therapists had cases. A total of 16 patients were
seen, with a mean of 2.3 patients per therapist; the mean number of sessions was 8.8 (SD 8.5). Of these,
three completed ≥ 14 sessions. In 8 out of the 16 cases the GAD checklists (TCC and EoTC) were completed.
Reasons for ending therapy in the 16 patients were as follows: two clients completed therapy (one had
received 16 sessions and the other was well after 10 sessions), three clients completed prematurely as they
did not want to do ‘exposure’, two were unwilling to allow the recording of sessions, five had not yet
completed treatment and four withdrew (one moved, one was too busy to attend and two withdrew
without giving a specific reason).
Ease of supervision
Telephone supervision proved to be a useful way for the ToSCA expert supervisors to supervise the IAPT
supervisors. The IAPT supervisors were able to represent the views and queries that their local therapists
had raised. These are included in the summary of questions on the manual and treatment manual
(see Clarification and modification to treatment protocol as a result of the practice patient stage below).
Adherence and competence
The TCC and EoTC checklist were completed or partially completed for 8 of the 16 participants seen. The
supervisors considered the therapists to be adherent according to the checklist, but noticed that the most
common component of the protocol that was omitted was the written exposure.
The supervisors considered the therapists to be competent on the basis of listening to excerpts from their
sessions, but none had rated a full session using the CTS-R because of the time required to do so and the fact
that not all of the ‘practice patients’ were being recorded as consent had not been provided for recording.
Clarification and modification to treatment protocol as a result of the practice
patient stage
Improving Access to Psychological Therapies protocols
l Patient attendance: the aim in the trial would have been to encourage the therapist to be proactive
about following up patients and not to discharge participants unless they had failed to attend at least
two sessions without notice.
l Clarification of what constituted a ‘step 2 IAPT intervention’: the protocol required patients to have
received a step 2 IAPT intervention prior to being referred into the study. This was clarified and
confirmed early on in the CBT group discussions (see Figure 1).
l Spacing of sessions: the Dugas treatment manual (see Appendix 13) indicated that patients should attend
14 sessions if possible, to be delivered within 16 weeks. For some, however, they might only complete
treatment by 26 weeks. In the practice patient stage, some supervisors reported patients recovering
within 10 sessions. It was agreed that if the therapists wanted to discharge patients after fewer than
14 sessions then they should make sure that patients were truly asymptomatic by asking them to
complete the Penn State Worry Questionnaire,60 which is the problem-specific measure of GAD within
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IAPT services as well as the GAD-7. If their responses to the questionnaire indicated that the patient was
within the normal range and had recovered fully, then they could be discharged with the reasons for this
being clearly recorded. It was also agreed that such patients should have received at least two sessions
dedicated to relapse prevention.
Study protocol
l Adherence to the manual: the agenda should be set with the patient at the beginning of treatment,
consistent with the collaborative approach of CBT, and included in this should be a full clinical
assessment of the patient and also a risk assessment, to be conducted during the first 20 minutes of
the session. It was agreed that all of the modules in the manual should be covered, but that modules 4
(problem-solving) and 5 (written exposure) could be swapped around. In some clients there was a
concern that problem-solving may be used as a way of reducing their tolerance of uncertainty and this
could be addressed by delaying the problem-solving module.
l Consent: a prerequisite of participating in the trial is that the patients have agreed to their session
being audio-taped.
l Specific therapeutic interventions: it was accepted that some exposure tasks may be more effective
than others and the therapists were encouraged to be flexible in their approach. They requested a
relapse prevention sheet, which was provided by Michel Dugas (see Appendix 16). The therapists were
encouraged to undertake exposure to uncertainty experiments in a graded way with their patients,
in order to make them more manageable and facilitate engagement.
ToSCA participants (internal pilot proceeding to full trial)
Clear progression criteria were developed and stated to allow progression from the internal pilot to the full
trial. One of these criteria was that the therapy could be delivered competently and that the therapists
could adhere consistently to the protocol. This was operationalised as stating (1) that the therapists, during
the internal pilot, should score a minimum of 36 on the CTS-R within 10% of randomly selected tapes
independently rated by the external assessor, and (2) that a minimum of 60% of the components of the
protocol had been delivered according to external assessor ratings on the EoTC. The random selection of
10% of audio-tapes taken from the total number of audio-recorded sessions delivered to all patients is
commonplace in trials as it ensures that the quality of therapy is representative and the interpretation likely
to be generalisable.
Confidentiality
The project aimed to use Data Safe Haven to transfer and store audio-recordings of therapy. This service
provides a technical solution for storing, handling and analysing identifiable data. It has been certified to the
ISO27001 information security standard and conforms to the NHS Information Governance Toolkit. This is
built using a walled garden approach, in which the data are stored, processed and managed within the
security of the system, avoiding the complexity of assured end point encryption. A file transfer mechanism
enables information to be transferred into the walled garden simply and securely (see Chapter 3, Research
governance).
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Chapter 7 Public and patient involvement
Introduction
Public and patient involvement (PPI) for ToSCA was arranged by the McPin Foundation. The McPin
Foundation is a mental health research charity with a particular specialism in the involvement of those with
experience of mental illness in research.61
The McPin Foundation additionally supports service users to carry out research in their own right in
collaboration with others. PPI in ToSCA took two forms: first, from Thomas Kabir, one of the study
co-applicants; and second, from a group of four service users known as the ToSCA Clinical Advisory
Group (CAG).
As the research was the result of a commissioning brief, PPI perhaps had less of an impact at the design
stage of the study than would otherwise have been the case. Nevertheless, the study had PPI input in the
application for funding and at all subsequent stages of the research.
Methods
Clinical Advisory Group
The CAG was made up of three service users plus the PPI co-applicant. The CAG met roughly three times
per year. Ad hoc meetings were held as needed. The responsibility for organising CAG meetings was held
by the PPI co-applicant, Thomas Kabir, who is employed by the McPin Foundation.
The CAG members were recruited via an open advertisement. The three people that were subsequently
recruited all had personal experience of anxiety. Meetings were chaired by Thomas Kabir. Members of the
wider research team were invited to attend meetings, and all meetings were minuted. The minutes of CAG
meetings were shared with the research team.
A total of six CAG meetings were held between August 2014 and June 2016. As per the NIHR’s INVOLVE
Briefing Notes for Researchers,62 CAG members were reimbursed for any out-of-pocket expenses.
Members were offered payment for attendance at meetings.
Thomas Kabir was the PPI co-applicant for the study. He provided input into the application for funding to
the HTA programme as well as the application for ethical approval. He later:
l sat on the Trial Management Group (TMG)
l attended TSC meetings as an observer
l recruited and organised CAG meetings
l acted as a link between the CAG and the wider study team
l advised on the recruitment materials for the study
l provided ad hoc advice to the study team as needed.
Reflections
A major initial focus of the CAG was on measuring the acceptability from a patient perspective of the two
interventions being tested against each other: sertraline and CBT. Developing ideas about how to measure
the acceptability of both a psychological therapy and a medication proved to be a particular challenge.
In the end, the decision was taken to use the Client Satisfaction Questionnaire (CSQ). The CAG disagreed
with this decision, as the CSQ appeared to focus on satisfaction with services rather than treatments per se.
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However, the TMG decided on the CSQ because of the perceived need to use one questionnaire to get
participant feedback about both interventions in order to be able to use this in the analysis, and no other
questionnaires were found that were able to be used to do this.
A related issue arose when dealing with the issue of what outcome measures to use in the study. CAG
members felt that the adverse effects of both CBT and sertraline should be measured. This posed a
problem, as it proved that there were no measures that were truly applicable to both a medication and a
psychological therapy. The CAG suggested using a modified form of the Toronto Side Effects Scale, but
the wider study team did not see this as an adequate solution as it was designed with drug-related side
effects in mind. The CAG felt that a modified version, taking out some of the terms, could still work, but
the wider study team felt it was not possible within the trial timelines to proceed with this. Additionally,
there was some debate within the wider study team as to whether or not adverse events that would not
be classified as serious in nature should be measured at all, and the TMG noted that the side effects of
sertraline have been fully documented in other studies. CAG members held the view that although this
was true, the adverse effects experienced by people actually taking part in the study needed to be
considered. The idea was that both the adverse and beneficial effects experienced by study participants
needed to be weighed against each other to get a true notion of the net worth of the treatments
being considered.
As the study progressed, more attention was given over to recruitment issues by CAG members and the
PPI co-applicant. CAG members felt that the responses made by the TMG to the recruitment issues that
the trial faced were appropriate. Indeed, it was felt that the study team had done all that they could to
address the recruitment problems that the trial faced. It was noted from an early stage that recruitment
to the study would be challenging. The following extract from the minutes of a CAG meeting held in
November 2015 summarised the CAG’s position:
A possible downside to taking part in the study is that participants will have no choice about whether
they take medication or CBT. Outside of the study people can potentially access both treatments.
This is clearly a barrier to participation.
Specific suggestions were made regarding how low-intensity IAPT workers could introduce the study to
potential participants. One CAG member wrote a script for IAPT workers to use, which was then shared with
other study team members and used in the revised version. More practical issues, such as how best to ask
female participants to take a pregnancy test as part of the baseline eligibility interview, were also discussed.
The recruitment strategies that were identified by the study team were fully discussed by the CAG.
Summary and recommendations
After the decision had been taken to close the study, a final meeting of the CAG was arranged. This was
at the suggestion of both the PPI co-applicant and CAG members.
l Two CAG members felt that communication with them about the study could have been more regular
and ongoing. It is recognised that this was as a result of staffing issues within the study team that were
beyond anyone’s control.
l The CAG patient voice could have been a bit stronger in the study. It was recommended that at least
two lay people sit on both the TSC and TMG. There was only one lay member formally on each group.
l It should have been made clearer what could have been measured as part of the study and what could
not (i.e. looking at side effects and adverse events of sertraline and CBT).
l CAG members said that they had enjoyed their experiences. One member said that her involvement
with the McPin Foundation had been a positive experience. This involvement had helped her become
involved in other research studies.
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l Everyone felt that the size of the CAG was appropriate. The relatively small size of the CAG enabled
the group to discuss quite complex matters in depth. CAG members thought that this might not have
always been possible with a larger group.
l All members of the CAG fully recognised the challenges inherent in the study attributable to comparing
two distinctly different treatment modalities in which patients are likely to have a preference of one over
the other, thus leading to huge challenges in recruitment.
Questions from the Clinical Advisory Group as a result of the study
l The CAG asked if the funder had sufficiently foreseen the potential recruitment problems with the
study. The CAG felt that there would be significant numbers of people who would prefer to receive
CBT rather than sertraline from the outset. This may have meant that a different study design may have
been more beneficial.
l CAG members asked if the commissioning brief for the study was reviewed by people with experience
of mental health problems specifically. If so, did these people identify the potential recruitment issues
that may arise from the original commissioning brief?
Recommendations for future research
l It seemed that there are relatively few treatment acceptability measures in routine use. It was felt that it
would be useful for the NIHR or another funder to fund research into developing a treatment acceptability
measure that would be of broad use within a mental health research setting. Within the context of
ToSCA, a measure that would work across different treatment modalities (a drug and a psychological
therapy) was needed.
l Likewise, there are few (if any) measures that can be used to measure the adverse effects of both a
drug and a psychological therapy. Again, it was felt that it would be useful to develop a measure that
could be used across different kinds of interventions.
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Chapter 8 National Institute for Health Research
Health Technology Assessment monitoring meeting
Recruitment was always the main concern of this study. Over the first 2 months of recruitment, six potentialparticipants were identified in the only pilot site at that time open to recruitment. Although this met our
anticipated recruitment rate of two participants per pilot site per month, the majority of those identified (4/6)
declined to participate in the trial, largely because they were reluctant to be randomised to the medication
arm. This trend persisted in the other sites and raised concerns about the study achieving the required
numbers over the internal pilot recruitment period. In view of this, the focus of the TSC meeting that was held
on 29 September 2015 was to develop an advance plan for an appropriate recruitment strategy. An analysis
of the reasons for low recruitment was conducted and discussed at this meeting. However, the main reasons
for poor recruitment did not change over time and some of the main reasons for non-participation in the trial
by eligible patients, based on the data obtained until the closure of the study, are listed in this chapter.
Review of reasons for poor recruitment
1. Patients’ preferences were by far the most important reason for the non-participation of 45 of the
60 potentially eligible patients (see Table 3). Of these 45 participants, 30 did not want to take any
medication and one for not more than 6 months; four wanted only CBT; one wanted a combination
of antidepressants and CBT and one went to their GP to obtain this; one was already on medication
(SSRIs); one found it hard to engage with CBT; two did not think that their GAD was their main clinical
priority; two did not want to take part in research; one did not give any reason for not taking part; and
one travelled extensively and, hence, could not keep regular clinical appointments as would have been
expected with participation in the trial.
2. GP factors contributed to the non-participation of four of the remaining potentially eligible patients.
In two such instances the GP was reluctant to prescribe medication and take part in the study, and in
two cases the GP decided to start sertraline even though they were aware of the trial.
3. IAPT and the PWPs: informal discussions with the PWPs suggested that participants who were potentially
eligible to take part but also had concomitant mental health comorbidities (i.e. depression, health anxiety
and social phobia) were excluded as possible participants in the study by the PWPs as they perceived that
these comorbidities would need to be treated first over and above any GAD. This was compounded by
the fact that patients with GAD, by virtue of their illness, were likely to express considerable uncertainty
about participation in a trial when approached to participate. This was then also perceived by the PWPs
as a reason for excluding them from the study. In addition, potential participants often slipped through
the recruitment net in the face of conflicting clinical pressures. Finally, and most importantly, recruitment
via a psychological therapy service (i.e. IAPT), as per the HTA programme brief, was biased towards a
pool of people who were expecting to receive psychological (CBT) therapies. This meant that presenting
such patients with a randomised option of drug or psychological therapy was poorly received, especially
considering that they were expecting to receive the latter.
Trial Steering Committee response
These issues were fully explored at the TSC meeting on 29 September 2015, and the chair of the TSC
wrote to the HTA programme informing them of the recruitment figures and of the various strategies
(please see the following paragraph for further details) that the study team had been working on to
address this issue. In response to this letter, the HTA programme arranged a monitoring meeting for
14 January 2016 to discuss both the reasons for the poor recruitment levels and to explore possible
alternative methods that could address this issue. At the meeting, a presentation of the various strategies
that were adopted by the trial team to enhance recruitment was summarised.
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Health Technology Assessment monitoring meeting: strategies adopted to enhance
recruitment
1. PPI input to enhance recruitment: we had worked closely with our PPI co-applicant, Thomas Kabir, and the
PIs at each clinical site to enhance recruitment by offering eligible participants a balanced view of both
drug and psychological treatments for GAD. We refined, with help from the PPI CAG, a user-accessible
script that the PWPs would adopt to offer an unbiased account of both treatments while also tackling
concerns that people had about antidepressant therapy. This was intended to be discussed with all people
with a GAD-7 score of ≥ 10 on completion of step 2 IAPT treatment.
2. Engaging with PWPs at the sites to ensure that they were actively recruiting to the study. This was
done by:
i. the trial team regularly attending PWP site meetings, in which they reminded PWPs about the trial
and were available to address any queries
ii. weekly telephone contacts with sites by ToSCA to field any queries on participant identification and
baseline assessments
iii. 2-monthly teleconferences at which all pilot sites discussed and shared information about effective
recruitment strategies.
3. Other methods used to identify eligible patients were:
i. assisting the identification of potentially eligible people through the IAPTUS database (IAPT’s electronic
clinical system), as an additional mechanism of identifying potential participants. We initially worked
with the lead PWPs in Camden, Islington and Kingston on running the following searches:
– retrospective searches to identify potentially eligible people missed by the PWPs during their
clinical reviews at the end of their step 2 treatment
– prospective searches to identify potential participants at their entry to the step 2 treatment
(i.e. those with high GAD-7 scores not on antidepressants) and alerted the PWPs in advance
about their possible eligibility
ii. IAPTUS prompts to PWPs of potentially eligible people: we were working with the IAPT data
managers on generating a computer prompt on the IAPTUS database in order to flag potential
participants, as described in the paragraph above. This, however, was not finalised and, hence,
not implemented
iii. approaching people on the waiting list for step 3 (high-intensity therapy): we explored the possibility
of getting eligible people to take part in the trial but, as they were on the waiting list for CBT, they
were expecting to receive psychological treatments and, hence, this approach did not yield any
participants
iv. opening new pilot recruitment sites: on 13 November 2015 we proposed the recruitment of more
clinical sites to boost our study numbers. We had received recent expressions of interest from six
sites through our contact with the CRNs and NHS trusts, as well as several over the past year that
the study had been advertised on the web. When approached, four sites expressed a definite
interest in taking part in the study, but after further discussion only two of these were willing to
actively recruit.
These strategies were discussed at the HTA programme monitoring meeting on 14 January 2016. It was
made clear that despite all the efforts that had been made by the trial team, recruitment to this study
was unlikely to achieve our final target number of 360 participants and we suggested that we alter
our recruitment strategy through a protocol change. Prior to the HTA programme monitoring meeting,
in discussion with the TSC, we had considered two possible future protocol changes: options A and B.
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We requested that one of these two, or both used in succession, be adopted following our meeting with
the HTA programme monitoring committee. These two options are detailed below:
1. Option A – this would have involved a drive to identify more people in primary care through a
retrospective search of GP databases to identify all adult patients aged ≥ 18 years with Read codes63 for
anxiety/depression and/or GAD-7 scores of ≥ 10. Letters would then be sent to those so identified
containing a reply slip, consent form for screening questionnaires, GAD-7 to complete, exclusion criteria
assessment checklist and a brief questionnaire asking them to express interest in participation in the
study. This approach aimed to maximise the identification of patients with GAD in primary care, and to
refer them on to the local IAPT services. The TSC were supportive of this change of protocol as it was
consistent with the HTA programme commissioning brief. They were concerned, however, that such a
strategy could overwhelm the local IAPT services, which were likely to already be under pressure and
may not have been prepared to deal with more referrals. Furthermore, there could be a significant delay
while people were receiving step 2 treatment before they became eligible for participation in the trial.
This could then lead to high levels of dropout. Nevertheless, the advantage of such an approach was
that it was tied in with the changes we had already implemented to enhance recruitment from within
IAPT services.
2. Option B – the process of identifying suitable patients in option B would have been similar to that of
option A. We would have run a retrospective search of GP databases to identify all adult patients aged
≥ 18 years with Read codes for anxiety/depression and/or GAD-7 scores of ≥ 10. Letters would then be
sent to patients containing a reply slip, consent form for screening questionnaires, GAD-7 to complete,
checklist of exclusion criteria and a brief questionnaire asking them to express an interest in taking part
in the study. Suitable patients would then be assessed for their eligibility to take part in the trial in
general practice and then be randomised to either the sertraline medication arm or high-intensity CBT
without having to engage with the step 2 treatment as delivered by the PWPs.
Option B would have been essentially a move from the original question proposed in the HTA programme
brief as it involved a change in research population. Rather than pointing people towards IAPT teams for
step 2 treatment (as in option A), this option would have recruited to the trial without a step 2 intervention.
This in itself is an important clinical question, but would have constituted a move from the HTA programme
brief as the study would not recruit merely those who have failed to respond to a step 2 intervention as
specified in the brief. The TSC initially felt it premature to consider such a departure without (1) testing the
effectiveness of the planned current changes to recruitment that would adhere to the HTA programme
brief, and (2) seeking the opinion of the funder, the HTA programme, as to whether or not this amendment
of the protocol (and thus research question) should be held in reserve if other changes, as described above,
had failed to improve recruitment.
Finally, a radical suggestion, bearing in mind that patient preferences are a major hurdle to recruitment,
was to design a patient preference trial in the form of a comprehensive cohort preference trial.
The HTA programme monitoring committee was not supportive of option A as this was an approach that
would not be adopted within the NHS in the future, even though the proposed protocol change would
have adhered to the HTA programme brief. The committee did consider option B to be a viable strategy
but, as it represented a significant deviation from the original commissioning brief, they wanted to consult
with the HTA programme director in order to arrive at a final decision. At the conclusion of the HTA
programme monitoring meeting the trial team was advised to persist with efforts to recruit until further
notice was given by the HTA programme regarding whether or not they would allow a deviation from the
original commissioning brief. If this was not considered acceptable, we were advised that the trial would
be expected to close down, hence bringing the study to an end.
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Final decision to close down the trial
On 29 January 2016, following discussions with the HTA programme director, we were informed that a
deviation from the original commissioning brief was not considered acceptable and the study should be
brought to an end. The principal reasons for this decision were as follows.
1. Fairness, in that any research team that would have submitted a proposal if the commissioning brief
had included option B, but chose not to because they felt the commissioning brief as it stood was not
feasible or appropriate, would have legitimate cause for complaint if we subsequently proceeded to
follow option B.
2. Option B involved a substantial change to the study population and would therefore represent a
different research question to that originally commissioned.
3. Option B would appear to deviate from NICE guidance; it was not clear if this would be acceptable to
the clinical community.
Following this decision we stopped recruiting to the trial and plans to close the trial down were developed
and implemented from 1 March 2016.
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Chapter 9 Conclusions and recommendations:
implications for practice and research
Main conclusions
Low rates of identification of potential participants
It was unfortunately not possible to recruit sufficient participants to the trial of CBT versus sertraline
following the recommended brief. The main barrier appears to have been at the level of identification of
potential trial participants by the IAPT PWPs. There are a number of possible reasons for this, which can be
summarised as follows:
1. The PWPs potentially having a bias towards psychological therapy as the treatment of choice and
finding it difficult to maintain clinical equipoise when talking to the patients about the trial.
2. The PWPs being aware that having GAD meant that these patients found uncertainty very difficult and
that the prospect of being randomised to a RCT for their treatment with the associated uncertainty of
this was particularly difficult for them to manage; the PWPs felt uncomfortable raising something that
might make their patients more anxious.
3. Some PWPs considered that the prevalence of GAD, or having this as the main clinical problem that
patients wanted to address, was lower than suggested by the trial team and they were very keen to
ensure that the patients they suggested the trial to definitely had GAD, despite the research team
explaining that a definitive diagnosis could not be made at the routine PWP level.
4. Several PWPs raised the issue to their clinical supervisors, suggesting that a patient’s comorbid clinical or
psychosocial problem was more important to address than their GAD. In such cases, the research team
encouraged both the PWPs and their supervisors to consider suggesting to patients that they might be
assessed for ToSCA if they had significant GAD.
5. Most PWPs had significant clinical workloads and it was difficult for them to also include the time
needed to raise the possibility of being assessed for the trial with suitable patients.
Patient factors affecting recruitment once they had been identified
The reasons given by many of those patients who had been identified as not wanting to be recruited into
the trial largely mirrored what the PWPs had suggested, in that by far the most significant reason given
was that the patient did not want to risk being randomised to the sertraline arm of the trial, and several
expressed a clear preference for wanting CBT treatment. Not wanting to be given medication appeared to
be the predominant factor, although finding the uncertainty of the randomisation process difficult may
also have been a factor. In retrospect, the nature of GAD – worry when there is uncertainty – should have
alerted us to the likelihood that discussions about the study and the uncertainty raised by randomisation
would prove challenging.
The reasons people gave for declining to participate were predominantly that they were unwilling to try
antidepressant medication or that they were clear that they wanted psychological treatment. Although
surveys indicate that people commonly report a preference for psychological over pharmacological
treatment for common mental health problems, the number of people unwilling to consider antidepressant
medication in our study was in excess of what would be expected from these surveys. One possibility is
that the context of recruitment within an IAPT service may be significant. The service is focused on
psychological treatments (in its name as well as in its treatment provision), and this sets a context for both
patients and staff. The IAPT staff approaching patients about the study, however much the need for
equipoise was discussed with them, are likely to have had an allegiance to psychological interventions and
may have subtly communicated this to potential participants. Even if this did not happen, people opting to
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be seen in an IAPT service in the first place are likely to be those interested in psychological treatment and
they may well have had less favourable views towards pharmacological treatments.
Another factor that was less of an issue than we had expected and made assumptions for was comorbid
major depression – only one patient of the seven who had a baseline assessment was found to be
ineligible because of major depression on the MINI questionnaire, which was much lower than we had
expected with our 50% estimate, although the number of patients assessed was small. It may have been
that by being very selective in the potential patients they identified, the PWPs had excluded those who
were clearly significantly depressed. The other patient found to be ineligible at the baseline assessment
had found it difficult to be sure whether or not GAD was the main psychological difficulty for which they
wanted treatment – after discussion with the TMG we clarified the wording of this screening question to
make it less potentially ambiguous.
In advance we had assumed that two-thirds of people meeting criteria for the study in other respects
would either be on antidepressant medication or decline to participate. In the event, a little over one-third
of potentially eligible people were already on antidepressant medication, and one in five participants
approached ended up agreeing to participate in the study.
The fact that two GPs declined to support their patients in their wish to be assessed for the trial was
disappointing, but it is difficult to know how we could have avoided this, given the trial design that recruited
participants from IAPT who could be registered with any of the GPs linked to that service. The only way to
have avoided this would have been to consider only patients whose GPs had agreed in advance to be
involved in study, but the response rate to a request from the local research networks for interested GPs to
state this was very low, which was not very surprising given that the chances of them having a patient
selected to take part in the trial were not high. The only other way to deal with this issue would be to recruit
directly from primary care, which is a strategy we considered (please see the following section) and suggested
to the HTA programme at the monitoring meeting, but this was turned down by the funders because it
would have been a major alteration to the commissioning brief.
Systemic factors affecting participant identification and recruitment
Linked with this is the fact that the advent of the national IAPT programme in England has meant that CBT
and related evidence-based psychological treatments are now readily available and accessible as standard
treatments. This means that if people have a preference for CBT they can access this relatively easily, in the
same way that people have for much longer been able to easily access antidepressant medication via their
GP. When access was more difficult, people might have been more prepared to consider a trial, but now if
people have a preference they may well exercise this through opting for their preference. Two potential
participants demonstrated this by stating a wish to have both CBT and antidepressant medication when the
study was discussed with them.
An alternative treatment strategy would have been to recruit from primary care. In primary care, the full
range of people with GAD would have been available to recruit, and primary care is where initial discussions
naturally take place about treatment options between drug and psychological treatments. People are more
likely to be in equipoise between drug and psychological treatments at this point than focused towards
psychological treatments, as they are later in an IAPT service and, accordingly, are likely to be more open to
accepting randomisation. They would also be less likely to already be on medication. This recruitment option
was not available to the study team as the commissioned brief was, following the NICE stepped-care model,
specifically to target people who had not improved following a low-intensity psychological intervention.
Arguably, the restriction in the total GAD population from the brief as given would have limited the
generalisability and utility of the findings even if recruitment had been successful, and recruiting from the
wider primary care population would have been more useful and generalisable in the clinical sense. However,
it is possible that, even if recruiting in primary care, people would have clear preferences between medication
and psychological treatment and, as both are now relatively easy to access in England, they might well
exercise that choice and be unwilling to accept randomisation to one or other intervention.
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Future research and training recommendations
1. Running a RCT of medication versus psychological therapy involving two interventions that are already
readily available to patients through the NHS is likely to have significant recruitment problems because
many people will prefer not to be randomised if they are able to choose the treatment they would
prefer. This was likely to have been further compounded in this trial by recruiting participants from a
psychological therapy service and the difficulty of dealing with the uncertainty of randomisation for
people with GAD. However, the unanswered question of whether psychological therapy or medication
is more effective for people with GAD remains.
We would suggest that potential funding bodies consider a call for a randomised trial of medication
versus psychological therapy for patients recruited from primary care, as this is where the discussion
about treatment choice is likely to occur. Those randomised to the psychological therapy arm could
be offered a low-intensity intervention initially and, if they do not improve sufficiently, proceed to
high-intensity CBT, with the treatment paths in both arms of the trial clearly documented over the
12-month follow-up. The number of people accepting or declining treatment at each step would
provide useful additional information.
Alternatively, a design that is more likely to reproduce the way in which patients are offered the
choice between pharmacological and psychological therapy in practice would be to recruit participants
with GAD from primary care to a randomised trial of a pharmacological therapy versus high-intensity
CBT without them being referred for a step 2 intervention. This would not be following the NICE
stepped-care model, but many patients are likely to be offered the choice between medication and
psychological therapy at this stage by their GP and may be more willing to accept being randomised to
one of the two interventions, allowing a direct comparison to be made.
2. Given the reluctance of patients to be randomised in this trial (both because of a reluctance to consider
randomisation to the medication arm if recruited from the IAPT service, but also because of the
uncertainty associated with randomisation, which people with GAD are likely to find particularly difficult),
we would suggest that a patient preference design is considered. This could be a comprehensive cohort
preference trial design, with patients allowed to choose whether they wish to opt for their preference of
treatment or would be happy to be randomised to either intervention, with both cohorts being followed
up for the duration of the study and the outcomes in the preference arms compared with the outcomes
in randomised arms. However, it is possible that even recruiting via primary care, too few people may
agree to be randomised to either intervention.
The recommendation would, therefore, be that if randomisation is not possible (either with recruitment
via IAPT or primary care) then a naturalistic cohort design should be considered, following people up in
accordance with their choice of treatment over a 12-month duration.64,65 It would be important to
accurately document all psychological comorbidities that might have an impact on the outcome.
A further possibility would be to use a Zelen’s preference design,66 with participants being randomised
before their informed consent to participate has been obtained, and then being offered the treatment
to which they were randomised. This would remove the intolerance of uncertainty as a potential barrier
to patient involvement but is likely to also result in significant numbers not wanting to take part, thus
reducing external validity. Ethics concerns may also be raised about using this design.
3. GAD appears underdiagnosed in primary care, for a variety of reasons, including imprecise diagnostic
classification by GPs, which may have a negative impact on the outcome of people with this disorder. It
would be helpful to conduct a study assessing patients diagnosed by their GPs as having depression or
other anxiety disorders to see to what extent they may have been misdiagnosed, and conditions such as
GAD or other psychological disorders underidentified.
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The recommendation would be for a study examining the prevalence of GAD in a primary care
population, possibly by reassessing patients diagnosed with a variety of depressive and anxiety disorders
with a more detailed gold standard psychiatric instrument. This would also be helpful in establishing the
numbers of people with ‘primary’ GAD, in which their GAD was their predominant concern, and those
with comorbid depression or other anxiety disorders that were more of a concern to them.
A further recommendation would be to include semistructured interviews to establish if patients
identified as having GAD saw this as a priority for treatment or if depression or other comorbidities
were likely to be higher priorities for them.
4. Identification and recruitment of potential participants from our pilot IAPT services proved difficult,
despite the enthusiasm of the IAPT leads at the various sites and the fact that we had expressions of
interest from a significant number of other IAPT sites around England if the trial continued to the next
stage. This was, however, a difficult role for the PWPs to undertake as it was clear that they had a
heavy clinical commitment and little experience of research apart from the lead PWPs at each site, who
were very energetic in their attempts to improve the recruitment rates.
We would suggest that training in research methods becomes a more formal part of PWP training if
they are to be involved in recruiting for trials on a regular basis.
5. The PPI CAG identified a lack of suitable patient acceptability and adverse event measures that could be
applicable to both the medication and psychological therapy arms of randomised trials.
Funding bodies may wish to commission the design of such an instrument for use in future RCTs.
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Appendix 1 Patient information sheet
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Appendix 2 Medication Suitability Review form
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Appendix 3 Informed consent form
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Appendix 4 General practitioner notification of
patient not being eligible
       
 
 
GP Notification of Patient Not being Eligible  
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Appendix 5 General practitioner notification of
randomisation outcome
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Appendix 6 General practitioner guidelines for
prescribing sertraline
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Appendix 7 Safety reporting information for
participants, general practitioners and Improving
Access to Psychological Therapies services
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Appendix 8 Generic site-specific information
justification
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Appendix 9 Training workshop for high-intensity
cognitive behavioural therapy therapists
The workshop covered background information, diagnostic criteria of GAD, the clinical presentation ofGAD, the cognitive behavioural model, and treatment and conclusions. Some specific questions about
the trial were raised during the training and were addressed by the CI and co-applicants.
The training consisted of providing information about the design of the trial, followed by taking trainees
through the six typical phases of the treatment protocol:
1. psychoeducation and worry awareness training
2. re-evaluation of the usefulness of worry
3. uncertainty recognition and behavioural exposure
4. problem-solving training
5. written exposure
6. relapse prevention.
The training was delivered as a workshop, with scenarios in which attendees were encouraged to get into
groups and practise using role play. It was based on the manual provided by Michel Dugas, and each
therapist and supervisor was given a copy for use in the trial (see Appendix 13).
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Appendix 10 Training for psychological
well-being practitioners
The training sessions followed a common presentation format covering:
1. rationale and design of the study
2. PWPs’ role in the study
3. GAD identification and diagnosis.
Presenting the rationale and design of the study included the context of the study in terms of the evidence
base for CBT and SSRIs as treatments for GAD, and the current lack of any head-to-head study determining
which may be the more effective treatment. The NICE guideline stepped-care model for GAD and the
associated clinical recommendations were presented in order to explain the choice needing to be made by
the patient and their clinician between CBT and SSRIs as treatment options at step 3 in the NICE stepped-
care pathway (see Figure 1). This provided the background for the study design as involving the recruitment
of patients who had not improved in a step 2 low-intensity psychological intervention, which is why PWPs
were critical to the identification and recruitment of study participants as they are responsible for delivering
low-intensity psychological interventions within the IAPT services.
Discussion of the criteria for identifying participants who might be suitable for the study and how best to
approach potential participants was the central part of the training.
Four key study criteria were set out for PWPs to use in considering patients they were treating:
1. that they were coming to the end of a low-intensity PWP treatment (having had at least three
treatment sessions)
2. that they still had a GAD-7 score of ≥ 10
3. that they might have GAD either as the sole diagnosis or comorbid with other diagnoses
4. that they were not currently, and had not for the past 8 weeks been, on antidepressant medication
(whether or not a patient was currently on a psychotropic medication was a data item that PWPs are
asked to routinely record at each appointment as part of national IAPT data requirements).
Questions from the PWPs and discussion around these criteria during the training sessions mostly
focused on:
l whether or not patients in all types of PWP treatment should be considered (the answer to this was
yes, with the exception of signposting interventions)
l whether or not to approach patients who, it was decided early in their low-intensity treatment, were
unlikely to progress (the answer was yes, as long as they had three treatment sessions)
l how sure they needed to be that someone had GAD (the PWPs were told that they did not need to
make a definitive diagnosis of GAD and were encouraged to be inclusive and refer to the study if they
thought there was a possibility the patient might have GAD).
Following the discussion around participant identification criteria, PWPs were given a script of what they
might say to a potential participant about the study (Box 3). The script was developed with suggestions
from a PPI member of the CAG (see Chapter 7).
The PWPs were encouraged to ask questions about this script during the training session and the
advantages for patients in taking part in research studies, as well as any potential barriers, were explored.
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Linked to this, the importance in randomised studies of discussing the two study arms from a position of
equipoise was emphasised. It was stressed that equipoise was the current state of evidence for this
important clinical question, but that they should be aware that they individually might well have a greater
investment in psychological than pharmaceutical treatments given that they were working as PWPs and
that this could potentially influence how they discussed the study with patients, including subconsciously.
How to guard against this was rehearsed.
The final element of the training was about the identification of GAD. GAD DSM-IV diagnostic criteria
were outlined and the differential diagnosis from other anxiety disorders and depression. Specific questions
PWPs might ask the patients when screening for GAD were described.
The length of the training sessions varied from 1 to 2.5 hours depending on the site.
The longer training sessions included more about the background to the study and longer sessions on
GAD diagnosis and identification (these sites had expressed an interest in using the study and the training
sessions as an opportunity to train their PWPs in the identification of GAD). One training session was held
for each pilot site, with the exception of Camden and Islington with Kingston, which had three training
sessions, one for each Borough service.
All the training sessions were delivered by one of the co-investigators (JC), who had established and been
the clinical lead of an IAPT service, so had a good understanding of the services and the role of PWPs
within this.
BOX 3 Suggested text for PWPs talking to potential participants about the study
There are two treatments recommended for the kind of worry and anxiety you have, when initial
treatment of the kind we have been working on together has not helped sufficiently. One is a type of
medication, the other is a psychological therapy and, although both have been found in many research
studies to be effective they have never been directly compared to see whether one is more effective than
the other.
Our service is participating in a national study comparing these two kinds of treatment and we are
therefore suggesting that suitable people take part, as there is evidence that people involved in medical
research often do better, whichever treatment group they are included in.
You might be interested to join this study and, if so, I can pass your details to a member of the research
team who would be happy to discuss it in more detail with you, or if you would prefer I can give you
a leaflet that explains more about the study and gives the details of how to contact the research
team yourself.
Might you be interested? However, if you are certain that you would definitely like to have one of these
treatments rather than the other it might be better that you didn’t volunteer for this study, as it will involve
people being randomised or selected by chance to be in one treatment group or the other.
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Appendix 11 Research staff training
Participants were given an introduction to the trial and its aims and objectives. The research staff had allhad some training in obtaining informed consent but were given an update and taken through the
ToSCA consent form as well as the structure and format of the eligibility check and baseline assessment
procedures. The procedures required asking female participants of child-bearing potential about the need
to have a pregnancy test as part of the eligibility criteria, and how to do this sensitively and interpret the
results was discussed and practised within the group.
The research staff then took part in interactive training in how to complete the relevant sections of the MINI.43
This involved working in pairs, taking it in turns to role play scripted vignettes of potential patients with pure
GAD (eligible) and also GAD with comorbid major depression and alcohol dependence (not eligible). The
group then discussed its results and any queries regarding results that differed from the agreed consensus.
Training was also given in completing the HAM-A.12 This involved one of the clinical co-applicants (JC or
MB) role playing a patient with GAD, and each trainee rating their symptoms and presentation for the
14 items of the questionnaire. At the end the results were once more discussed within the group to ensure
a consensus of within two points on each item.
The central research team produced a full training/recruitment manual for participating sites, with all the
relevant questionnaires and outcome measures as appendices for reference.
This was distributed in draft version to participants at the training sessions and the full electronic version
sent to the pilot sites when they were open to recruitment (manual available on request).
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Appendix 12 ToSCA general practitioner flyer
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Appendix 13 Cognitive behavioural treatment
manual for generalised anxiety disorder
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Appendix 15 End of Therapy Checklist
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Appendix 16 Relapse prevention sheet
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